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ABSTRACT 
 Transthyretin (TTR)-associated amyloidoses are diseases wherein wild-type or 
mutant TTR forms amyloid fibrils that infiltrate multiple organs.  Wild-type TTR 
amyloidosis, ATTRwt, is a sporadic disease characterized by deposits that occur mainly 
in the heart.  Alternatively, >100 TTR mutants cause inherited forms, ATTRm, frequently 
featuring cardiac amyloid deposits. 
The goals of this research were to create a cell-based model of ATTR 
amyloidosis, to define the mechanism of cardiac TTR-associated amyloid at the cellular 
level, and to study several agents that could interrupt the amyloid process.  We 
hypothesized that TTR oligomers were cardiotoxic and played a role in the mechanism of 
ATTR amyloidosis, and that cytotoxicity could be inhibited by diflunisal, doxycycline, 
and Kiacta®.  Focusing on TTR proteins associated with cardiac amyloidosis (wild-type, 
L55P, V30A, and V122), we developed a thermal denaturation method for creating TTR 
oligomers that allowed us to study the direct effect of oligomers on cells.  Congo red and 
thioflavin T analyses confirmed that the oligomers were on pathway to amyloid fibril 
formation.  We tested the effect of TTR oligomers on rat and human cardiac cells by 
measuring cell viability and stress response (through live protease activity and qPCR).  
  vii 
TTR-L55P oligomers elicited a cytotoxic effect; fluorescent microscopy indicated 
cellular uptake of the oligomers and continued intra-cellular aggregation.  Cytotoxicity 
was blocked when TTR was heated in the presence of doxycycline; the drug appeared to 
dissociate TTR aggregates or stabilize the monomeric forms.  We also investigated 
retinol-binding protein (RBP), a natural binding partner of TTR.  By immuno-
histochemistry, RBP was demonstrated in ATTRwt and ATTRm ‘non-amyloid’ 
transplant heart tissues, localized to areas containing amyloid or in the case of the 
transplant tissue, regions that appeared to display ischemic damage.  Serum RBP levels 
were significantly different in ATTR vs. age-matched controls (p = 0.03), and in ATTRwt 
vs. ATTRm (p <0.0001) by ELISA. 
These data provide evidence that TTR oligomers are cardiotoxic, possibly due to 
cellular internalization and progressive intracellular aggregation.  Furthermore, our 
results support the use of doxycycline as a therapeutic in ATTR to target these 
amyloidogenic oligomers, and suggest that RBP may have potential as a disease 
biomarker. 
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CHAPTER 1.  INTRODUCTION 
1.1 Protein misfolding and amyloid formation 
Proteins are key in the proper functioning of every system in our body; correct 
tertiary and quaternary folding of these biomolecules is therefore of vital importance.  
Many normal mechanisms and checkpoints are in place to monitor and ensure that 
proteins in the human body are present in native form and thus, properly functional.  The 
correct conformational state of a protein is achieved through a multistep folding 
mechanism that is mediated by molecular chaperones.  Chaperones facilitate and 
maintain protein native structure and are usually able to reverse incorrect or non-native 
folding. 
When a protein adopts an irreversible non-native conformation, it is removed by 
the cell through autophagy or proteosomal degradation[1], [2].  Aberrantly folded 
proteins can accumulate in the cellular environment when degradative pathways are 
impaired or overwhelmed.  Failure to remove misfolded proteins can have devastating 
consequences at the cellular and eventually tissue/organ levels; increased levels of non-
native proteins can lead to self-association of the misfolded subunits, subsequent 
development of soluble oligomers, generation of large molecular aggregates, and 
ultimately the formation and deposition of insoluble amyloid fibrils (Figure 1). 
Amyloid fibrils are non-branching, of indeterminate length, and rich in beta-sheet 
structure.  More than 25 proteins can form the backbone of amyloid fibrils[3].  Despite 
the sequence heterogeneity of amyloid proteins and amorphous appearance of the 
deposits by light microscopy, all amyloid fibrils exhibit a highly organized ultrastructure.  
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It is this ordered characteristic of the fibrils that imparts the unique, but consistent, dye-
binding properties used in the detection and identification of amyloid in tissue.  One such 
special stain is Congo red[4]; amyloid fibrils bind to Congo red and display a salmon 
color when observed by standard light  microscopy, and a unique apple green 
birefringence when viewed under polarized light[5] as demonstrated in Figure 2.  This 
histopathologic testing with Congo red is considered to be the gold standard for 
diagnosing all forms of amyloid disease[6].  In addition to Congo red, Thioflavin-T has 
also become a common tool to detect amyloid used more widely in laboratory settings[7], 
[8].   
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Figure 1.  Protein misfolding, degradation, and aggregation schema.  
The transition from the native to misfolded state of a protein can be reversed by 
chaperones.  When the native state cannot be preserved, misfolded proteins can be 
degraded through autophagy or proteasomal degradation.  If the degradation pathway 
fails, misfolded proteins will accumulate, self-associate, and progress to form larger 
oligomers that ultimately deposit as amyloid fibrils in tissue.  Reproduced with 
permission from Nature Publishing Group (Irwin et al.[2]). 
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1.2 Amyloidosis 
Amyloid fibrils can deposit in many different organs and tissue types; depending 
on the amyloid protein and target tissue, the deposits will result in a variety of 
pathologies collectively known as the amyloid diseases or amyloidoses.  Currently, 
approximately 30 amyloid proteins[9] have been identified, all capable of forming 
amyloid fibrils through a protein misfolding mechanism, but leading to very distinct 
pathophysiologies[10].  Some of the most well-known amyloidoses are Alzheimer’s 
disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD)[11], [12](Table 
1).  These diseases may be considered localized forms of amyloidosis characterized by 
amyloid deposition exclusively in one organ.  In Alzheimer’s disease, for instance, Aβ 
protein plaques in the brain are the pathological hallmark associated with dementia and 
neurodegeneration in patients[13]. 
In addition to the localized forms, there are the systemic amyloidoses in which 
multiple organs can be affected.  The most common systemic amyloidosis is 
immunoglobulin light chain or primary amyloidosis (AL), in which the amyloid is 
derived from the immunoglobulin light chain.  In AL amyloidosis, the most frequently 
affected organs are the heart, kidney, liver, and peripheral and autonomic nervous 
systems.  This multiorgan involvement results in a vast array of clinical features 
including cardiomyopathy, proteinuria, neuropathy, and hepatomegaly[14].  It is 
estimated that AL affects one in every 100,000 individuals in Western countries[15].  
Other types of systemic amyloidosis include both acquired and inherited forms usually 
associated with one of the plasma proteins.  We are particularly interested in the group of 
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systemic amyloid diseases linked to the plasma protein, transthyretin (TTR).  The TTR-
associated systemic amyloidoses are the focus of this dissertation and a further 
description will follow.  While these diverse pathologies with unique clinical profiles are 
caused by proteins with varying structures and functions, they are all characterized by an 
identical process that involves protein aggregation and amyloid fibrillogenesis.  The 
formation of amyloid can occur, regardless of the source protein native structure, and 
interestingly even the soluble oligomers display the same distinct amyloid structural 
conformations[16] composed of beta-pleated sheet and anti-parallel fibrillar structures. 
Though the presence of fibrillar amyloid deposits is well-established as a 
hallmark feature of all amyloid diseases, the extent to which these deposits cause such 
diverse clinical characteristics in these pathologies remains unclear and controversial.  
Though it was initially thought that the deposits were the main cause of disease, it is now 
believed that soluble amyloid protein oligomers[10], [12], [17] and pre-fibrillar species 
may be toxic entities that lead to disease presentation and progression in amyloidosis[18].  
In 2005, Cleary et al. were the first to show that soluble oligomers of Aβ disrupted 
cognitive function in a rat model[19] and in 2008, Sörgjerd et al. demonstrated in cell-
based studies that pre-fibrillar transthyretin (TTR) oligomers were toxic to neuroblastoma 
cells (SH-SY5Y), whereas mature amyloid fibrils were not[20].  
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Table 1.  Proteins involved in systemic and localized amyloid diseases. 
Reprinted from The International Journal of Biochemistry & Cell Biology, Invernizzi et 
al., Protein Aggregation:  Mechanisms and functional consequences, Volume 44, Issue 9 
(1541-1554), Copyright (2012), with permission from Elsevier[21]. 
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Figure 2.  Amyloid deposits demonstrated by Congo red histology.  
Light microscopic images demonstrating the presence of amyloid in heart tissue. (a) 
Congo red binds to the amyloid deposits as shown by the red staining, with the 
corresponding signature (b) apple green birefringence observed under polarized light.  
Images were taken at 10x magnification; scale bar represents 100 µm.  
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1.3 Transthyretin 
One protein that can undergo protein misfolding and transition to amyloid fibril 
formation is transthyretin (TTR).  Previously known as prealbumin, TTR is a 55 kD, 
homotetrametic protein mainly synthesized in the liver and choroid plexus; each of the 
four TTR subunits spans 127 amino acids in length[22], [23].  The protein is extremely 
stable structurally, a characteristic attributed to its rich beta-sheet content[24], and a 
sequence that has been highly conserved across vertebrate species[25].  In humans, TTR 
is mainly found in plasma and cerebrospinal fluid (CSF) at concentrations of 200-400 
g/mL and 10-40 g/mL, respectively[26], [27].  TTR functions as a transport protein for 
thyroxine (T4), a thyroid hormone, and retinol (Vitamin A) which is carried as a ternary 
complex with retinol-binding protein (RBP)[23].  T4 is carried in one of two binding 
pockets formed at the dimer-dimer interface of tetrameric TTR.  The T4 binding pockets 
have been shown to also have binding affinities for other small molecules such as 
diflunisal; diflunisal is a repurposed drug recently studied in an international clinical trial 
of patients with inherited forms of TTR-associated amyloidosis[28].  In addition, there 
are two sites on TTR for association with retinol-binding protein (RBP).  Figure 7 shows 
the TTR-RBP2 complex, also known as the transthyretin-retinol-binding protein complex.  
TTR binding sites for T4 and retinol-binding protein are separate and non-overlapping 
(Figure 3)[29].  
More than 100 point mutations in coding regions of the TTR gene have been 
reported and the majority are associated with inherited forms of amyloidosis[23].  
Previously known as familial amyloid polyneuropathy (FAP) or familial amyloid 
  
9 
cardiomyopathy (FAC) depending on the clinical phenotype, these diseases are now 
collectively referred to as mutant transthyretin amyloidosis (ATTRm)[30].  In addition to 
variant forms, wild-type TTR can also be amyloidogenic, i.e. form amyloid deposits; the 
amyloid disease associated with wild-type transthyretin amyloidosis (ATTRwt) has 
previously been referred to as age-related, senile cardiac (SCA) and senile systemic 
amyloidosis (SSA)[31], [32]. 
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Figure 3.  X-ray crystal structure of the transthyretin tetramer.  
Ribbon diagram of the transthyretin (TTR) tetramer.  The tetramer is composed of four 
identical monomers, each 127 amino acids in length.  There are two thyroxine (T4) 
binding pockets, one between each dimer-dimer interface and indicated by the arrows in 
the figure.  Source http://www.ott.csic.es/rdcsic/rdcsicesp/rdqu42esp.htm. 
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1.4 Transthyretin-associated amyloidosis 
The transthyretin-associated amyloidoses are systemic diseases in which wild-
type or a variant form of TTR becomes destabilized and forms amyloid fibrils that can 
infiltrate multiple organs.  Wild-type TTR amyloidosis, ATTRwt, causes a sporadic 
pathology characterized by deposits that occur mainly in the extracellular compartment of 
the heart.  In addition, over 100 point mutations in the TTR gene are responsible for a 
vast array of familial pathologies, ATTRm, that affect many different tissue systems[33], 
[34].  It is generally believed that all ATTR diseases share a common mechanism of 
amyloidogenesis.  Research studies suggest that the pathway begins with dissociation of 
the normally stable TTR tetramer into monomeric subunits; tetramer dissociation is 
thought to be the rate-limiting step for TTR amyloid fibril formation.  Following tetramer 
dissociation, it is believed that the individual TTR monomers become misfolded, i.e. the 
subunits adopt a non-native conformation, and this leads to subunit association, formation 
of oligomeric and pre-fibrillar aggregates, and eventually insoluble amyloid fibrils[8]. 
ATTRm amyloidosis 
There currently are over one hundred point mutations that have been reported in 
the TTR gene, most of which are amyloidogenic and lead to symptomatic amyloid 
disease[23]; these pathologies are designated as mutant TTR-associated (ATTRm) 
amyloidosis.  Clinical presentation and age of onset in ATTRm amyloidosis varies based 
on the underlying TTR mutation.  Certain amyloidogenic TTR variants commonly feature 
neuropathic involvement while others are linked to cardiomyopathy as the main clinical 
presentation (Figure 4).  In the past, these ATTRm diseases were termed familial 
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amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC), based on 
clinical phenotype[35]–[37]; this nomenclature is still used occasionally in the 
literature[38]. 
Kinetic and biophysical studies have shown that severity of disease and earlier 
age of onset correlate with the instability of the pathologic TTR variant protein[39], [40].  
ATTRm amyloidosis featuring presentation of symptoms at a younger age and a more 
aggressive progression of disease appear to be caused by TTR variants that, in vitro, are 
biochemically unstable and show an increased propensity to form amyloid fibrils[23], 
[41]–[45].  Examples demonstrating this phenomenon are TTR-L55P, -V30A, and  
-V122I (Table 2).  L55P, considered one of the most amyloidogenic of all TTR variants, 
and V30A are both associated with early disease onsets that occur in the early 20s and 
30s, respectively.  V122I features symptom development around age 60 or beyond[40], 
[46].  These three TTR variants, detailed further in the paragraphs below, were used in 
many of the studies presented in this thesis. 
The L55P point mutation results in the replacement of a leucine (L) residue by 
proline (P) at N-terminal amino acid residue 55 of the protein; this mutation is considered 
to be one of the most lethal, giving rise to a highly destabilized TTR protein[47].  Patients 
with the L55P TTR variant develop symptoms much earlier than most other forms of 
ATTRm and disease progression is more aggressive.  Clinical features include both 
cardiomyopathy and neuropathy (Table 2).  It has been demonstrated that this particular 
amino acid substitution leads to a significant decrease in tetramer stability and an 
increased tendency of L55P to form amyloidogenic species[45].  Moreover, Yang et al. 
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showed that the L55P monomer is significantly destabilized in comparison to wild-type 
monomers[46]. 
The substitution of an alanine (A) for a valine (V) residue at position 30 in the 
TTR protein was first described in 1992[34].  In patients with this amyloidogenic 
mutation, there is extensive amyloid deposition in various organs including the liver, 
peripheral nerves, and pancreas; a relatively young age of onset is also featured in ATTR-
V30A (Table 1)[33].  Similar to the TTR-L55P variant previously described, the TTR-
V30A mutant has been shown to be kinetically destabilized and this results in a TTR 
tetramer that can dissociate to form amyloid fibrils more easily compared to the wild-type 
protein[48]. 
First reported by Gorevic et al. in 1989[31], V122I results from a point mutation 
in exon 4 of the TTR gene and involves a substitution of isoleucine (I) for valine (V) at 
N-terminal residue 122 [23] of the protein.  This amino acid replacement has been shown 
to decrease the energy of activation in the rate-liming step of tetramer dissociation, 
leading to a higher amyloid fibril formation rate in vitro[49].  In 2006, it was reported 
that about 3% of the African American population carry the V122I mutation in the TTR 
gene[50].  In addition, Jacobson et al.[40] found that, in their cohort of African 
Americans presenting with cardiac amyloidosis, 23% had the V122I point mutation; 
moreover, the authors of this study reported that the risk for cardiac amyloid in African 
Americans over the age of 60 was four times greater than Caucasians.  
Patients with the V122I point mutation present predominantly with 
cardiomyopathy (Table 2) due to pervasive amyloid infiltration of the heart[40].  
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Consequently, disease treatment is aimed mainly at managing the symptoms of cardiac 
impairment.  If eligible, patients may receive a heart transplant or combined heart and 
liver transplantation[36].  Median survival in untreated patients with ATTRm due to 
V122I is 27 months [51]. 
Current treatment options for ATTRm include liver transplantation, removing the 
source of the aberrant TTR protein, as well as small molecule drug treatments.  Several of 
these small molecule therapeutics are currently in clinical trials treating ATTRm patients 
and preliminary results are promising[28], [52], [53].  
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Figure 4.  Phenotype of ATTRm amyloidosis mutations.  
Reproduced with kind permission of Springer Business and Science Publishing (Castano 
et al., 2014).  
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.  
Table 2.  Clinical phenotype and ages of onset associated with amyloidogenic forms 
of transthyretin (TTR). 
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ATTRwt 
In addition to the many TTR variants that can form amyloid and lead to systemic 
amyloidosis, the wild-type TTR protein can also misfold and cause disease despite the 
absence of a gene mutation[54].  The disease associated with wild-type TTR is referred to 
as ATTR wild-type amyloidosis, or ATTRwt, which until recently was known as senile 
systemic amyloidosis (SSA)[55].  Initially, the disease was considered a localized form of 
amyloidosis which exclusively featured heart involvement and was thus, originally 
termed senile cardiac amyloidosis (SCA).  In the early 1980s, Pitkanen et al. first 
described a systemic distribution of amyloid deposits that occurred in multiple organs 
throughout the body; the term senile systemic amyloidosis (SSA)[55] was coined.  The 
authors reported that histological screening of tissues from patients with SSA showed 
amyloid deposits in the lung, liver, and kidney even though the majority of cases 
demonstrated that the heart was extensively infiltrated. 
ATTRwt amyloidosis is an irreversible and life-threatening late onset disease with 
a median survival of less than 5 years[56]–[58].  The disease has been reported almost 
exclusively in men above the age of 60 years[57], [59], [60].  Cardiomyopathy is the 
predominant clinical feature in ATTRwt (Figure 4)[57] and patients frequently present 
with symptoms of congestive heart failure at time of diagnosis.  Echocardiographic 
evaluation usually reveals thickening of the left ventricular wall and/or valve, and an 
increase in the interventricular septal diameter.  Atrial fibrillation is also a common 
characteristic[59], [61], and almost half of patients present with carpal tunnel syndrome 
(CTS)[57]. 
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While once considered a rare disease, several reports have recently suggested that 
ATTRwt amyloidosis may be largely unrecognized and therefore, under-diagnosed.  The 
prevalence of the disease is unknown, but may be higher than previously appreciated[62].  
In fact, it is now believed that 25% of elderly men over the age of 80 have cardiac 
amyloid deposits composed of wild-type TTR[32]. 
Unfortunately, there is no cure currently available for patients with ATTRwt 
amyloidosis; treatment involves management of symptoms and palliative care.  The 
absence of treatments or therapeutic options for individuals afflicted with this disease 
represents a major unmet need for this patient population.  In addition, there is an urgent 
necessity for biomarkers of disease and indicators of progression; the diagnosis of 
ATTRwt amyloidosis is particularly challenging due to the fact that the amyloidogenic 
protein lacks any mutations or detectable abnormalities. 
 
1.5 Transthyretin and the heart 
The cardiac amyloidoses are the leading cause of infiltrative cardiomyopathy 
(CMP)[63] and can be divided into two types:  immunoglobulin light chain  or primary 
amyloidosis (AL) and the TTR-associated amyloidoses (ATTRm and ATTRwt).  Both 
AL and ATTR amyloidosis are confirmed by Congo red staining of a biopsy from the 
affected organ and identification of the amyloid deposited protein is accomplished by 
immunochemical or mass spectrometric analyses.  In cases of ATTRm amyloidosis, 
serum screening for the variant TTR protein can be achieved using isoelectric focusing 
(IEF) which has 96% sensitivity and 100% specificity; the presence and identity of the 
TTR gene mutation are determined using direct DNA sequence analysis[64].  For 
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ATTRwt, the diagnosis is more challenging; criteria include ruling out the presence of 
AL and ATTRm amyloidosis, and proof that wild-type TTR is the major component of 
the amyloid fibrils usually through mass spectrometric testing. 
The occurrence of TTR amyloid deposits severely impacts the structure and 
proper functioning of the heart (Figure 5).  Echocardiographic imaging in patients with 
ATTR amyloidosis frequently shows an increased interventricular septal thickness 
(IVST) in the absence of hypertension[59].  Patients also present with systolic 
dysfunction, lower left ventricular ejection fraction (LVEF) and a high frequency of 
intracardiac thrombosis[65], [66].  By electrocardiography, low-QRS voltage and 
arrhythmia[67] are commonly observed; laboratory values of brain natriuretic peptide 
(BNP) and cardiac troponin (c-Tn I) are elevated and seem to correlate with decreased 
survival although the exact relationship remains to be determined[58].  
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Figure 5.  Progression of ATTR cardiac amyloid disease parameters.  
As cardiac ATTR amyloidosis progresses, BNP and troponin levels rise whereas ejection 
fraction (EF) and functional status of the heart quickly fall.  Reproduced with permission 
from Springer Science and Business Publishing (Castano et al., 2004). 
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1.6 Current treatment and alternative strategies 
Treatment options for patients with TTR amyloidosis have been limited and are 
focused on either controlling the symptoms or interrupting the process of amyloid 
deposition in target organs.  The management of symptoms can range from painkillers 
and diuretics to prophylactic pacemaker placement in patients with CMP.  Orthotopic 
liver transplantation (OLT), used to treat ATTRm amyloidosis, is aimed at halting or 
slowing amyloid infiltration by removing the source of the variant TTR protein[68].  In 
addition, if the heart is severely affected, a patient may also receive an orthotopic heart 
transplant (OHT) or in some cases a combination of both OLT and OHT. 
It is important to note that several groups have reported signs of renewed cardiac 
infiltration in ATTR patients after liver transplantation[69], [70] and the development of 
amyloid in domino liver recipients much more rapidly than anticipated.  Okamoto et al. 
described continued development of arrhythmia in ATTRm patients following OLT; the 
authors reported that OLT did not prevent the development of heart arrhythmia in their 
cohort of FAP and in most cases pacemaker insertion was necessary[71].  Olofsson et al. 
also reported a progression of CMP after liver transplantation in their study of Portuguese 
patients with FAP[72].  The probability of survival, 5 years after OLT, was 77%[70]; 
survival, 2 years after OHT, was 67% in ATTRm and 100% in ATTRwt patients.  
While liver transplantation is aimed at slowing disease progression by removal of 
the amyloidogenic protein, an alternative therapeutic strategy seeks to halt the amyloid 
process by stabilizing the native tetrameric form of circulating TTR.  The mechanism of 
TTR amyloid formation is widely believed to feature an initial tetramer dissociation step.  
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Like thyroxine, compounds that bind to TTR in regions of the dimer-dimer interface 
could potentially block the propensity of TTR to be amyloidogenic.  Several compounds 
that reportedly act as TTR tetramer stabilizers are tafamidis, epigallocatechin gallate 
(EGCG), and diflunisal[41], [52], [73]–[75].  Tafamidis, 1-(3,5-dichlorophenyl)-1,3-
benzoxazole-6-carboxylic acid, is a drug designed specifically to bind TTR in the 
thyroxine-binding clefts and stabilize the tetrameric form of the protein[73].  Clinical 
trials of tafamidis have shown effective in vivo maintenance of native, serum circulating 
TTR in patients with FAP; however, data from these studies also indicated that the drug 
failed to halt disease progression as worsening of neurologic functions occurred in the 
treatment groups[52], [53].  The long-term tolerability and efficacy of tafamidis have yet 
to be determined and a Phase III trial by Pfizer is currently underway.  EGCG is an 
abundant catechin found in green tea that has been shown to bind TTR and prevent 
aggregation in vitro[74].  Diflunisal is a salicylic acid derivative that is classified as a 
non-steroidal, anti-inflammatory drug (NSAID).  The ability of diflunisal to act as a TTR 
tetramer stabilizer was studied as part of the research presented in this thesis and a further 
description of the drug will follow. 
Another approach to treating patients with ATTR amyloidosis targets the amyloid 
fibrils that constitute the deposits.  Doxycycline, tauroursodeoxycholic acid (TUDCA), 
and EGCG are being investigated for their potential to degrade amyloid fibrils.  The 
combination of doxycycline and TUDCA, an anti-oxidant, has been shown to lower TTR 
amyloid deposition in mice[76].  Moreover, in addition to stabilizing tetrameric TTR, 
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EGCG also appears to be capable of digesting preformed TTR amyloid fibrils in 
vitro[77].  
Since both wild-type and variant forms of TTR are amyloidogenic, it seems likely 
that factors extrinsic to TTR structural features, e.g. other plasma circulating or tissue 
specific proteins, may be involved in the formation of amyloid fibrils and deposits.  The 
extracellular chaperone, clusterin, is one example of an extrinsic factor that has recently 
been implicated in ATTR amyloidosis pathogenesis[75], [78].  Research into 
understanding the potential roles of such extrinsic factors and the protective effects of 
natural binding partners of TTR are of interest as results of these studies could lead to 
discovery or design of anti-amyloid agents. 
1.7 Potential therapeutics 
Currently, there are a number of research initiatives aimed at developing an 
efficacious treatment for TTR-associated forms of amyloidosis.  The treatment strategies 
are varied and target different steps in the process of TTR amyloid formation.  Agents 
that bind to TTR in the thyroxine pocket, stabilize tetrameric TTR and thus, inhibit 
amyloid oligomer and fibril formation[79].  Diflunisal and tafamidis are examples of this 
approach[80].  Alternatively, fibril degradation has been explored as a means of ridding 
the organ of damaging amyloid deposits; doxycycline is a drug with reported fibril 
disrupting activity.  In addition, heparan sulfate proteoglycans, commonly found in 
amyloid deposits, have been the focus of anti-amyloid agent development.  Specifically, 
sulfated glycosaminoglyacans (GAGs) have been targeted for their role in amyloidosis as 
they enhance amyloid deposition.  Compounds such as Kiacta®, are being tested as small 
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molecules that compete with GAGs to bind amyloid proteins and thus, prevent amyloid 
infiltration[81].  Diflunisal, doxycycline, and Kiacta® were used in our studies and are 
detailed further in subsequent paragraphs. 
As mentioned, diflunisal (Figure 6a) is a salicylic acid derivative classified as a 
non-steroidal anti-inflammatory drug (NSAID).  Diflunisal was previously shown in 
biophysical studies to stabilize the native state of TTR and slow amyloid fibril 
formation[75], [82].  In addition, efficacy of the drug was reported to be directly related 
to the relative thermodynamic stabilities of the various TTR mutants[83].  Under the 
leadership of Dr. John Berk at the Boston University Amyloidosis Center, a two-year, 
multicenter, international, randomized, placebo-controlled clinical trial studying the 
effect of diflunisal in patients with ATTRm amyloidosis has been conducted; findings 
from the study demonstrated that diflunisal, a repurposed drug, significantly reduced 
disease progression in a cohort of FAP patients[28]. 
Doxycycline, α-6-deoxy-oxytetracycline (Figure 6b), is a tetracycline antibiotic 
which was originally produced to fight bacterial infections such as Staphylococcus and 
Enterococcus[84].  In recent years, however, repurposing of the antibiotic has led to 
studies demonstrating an ability of the drug to disrupt fibrils in FAP mouse models[76], 
[85], [86].  Moreover, several groups have reported that doxycycline is capable of 
attenuating protein aggregation in an B-crystallin cardiac proteinopathy mouse 
model[80] and reducing fibril formation in an AL amyloidosis mouse model[87].
 
Kiacta® (Figure 6c) is a glycosaminoglycan mimetic also known by the generic 
name, eprodisate.  Originally, the drug was proposed as a potential anti-amyloid 
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compound to treat amyloid A (AA) or secondary amyloidosis by Kisilevsky et al.[88].  
Kiacta® is believed to act as a glycosaminoglycan (GAG) mimetic, specifically 
competing with the GAG structures in amyloid deposits and preventing further deposition 
of amyloidogenic material.  This drug is currently being studied in an ongoing, multi-
center, international clinical trial as a potential treatment to arrest renal function decline 
in AA amyloidosis (NCT01215747). 
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Figure 6.  Chemical structures of potential small molecule therapeutics.  
(a) Diflunisal (2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid), (b) doxycycline (α-6-
deoxy-oxytetracycline), and (c) Kiacta®, also known as eprodisate (disodium 1,3-
propanedisulfonate).  
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1.8 Retinol-binding protein 
A natural binding partner of TTR, retinol-binding protein (RBP) is a 21 kD 
monomeric protein that exists as one of five isoforms.  RBP4 is the most abundant and 
the only secreted isoform; it circulates in the bloodstream and binds approximately 50% 
of all circulating TTR at a 1:1 molar ratio[29].  The binding of TTR to RBP4 occurs at 
the C-terminus of the RBP molecule through non-covalent interactions[89].  There are 
two potential RBP binding sites on TTR and while the stoichiometry of the TTR-RBP 
complex in circulation is believed to be 1:1, some in vitro studies have demonstrated the 
formation of a 1:2 species with both available sites on TTR occupied (Figure 7)[90], 
[91].  However, in this latter situation, the binding of the first RBP molecule appears to 
have a negative cooperative effect; the affinity of the TTR tetramer for binding a second 
RBP molecule was shown to be significantly lower[92], [93].  
RBP4 functions as the only carrier of all-trans retinol (Vitamin A) in the 
circulation; transport of the vitamin is from the liver, where both RBP4 and TTR are 
synthesized [16], to target tissues throughout the body.  When bound to retinol, the RBP 
molecule is referred to as holo-RBP, whereas the unbound form is termed apoRBP [29].  
Retinol is an extremely hydrophobic molecule and thus, association with RBP occurs 
within the beta barrel structure of the RBP molecule[89], [94].  The RBP4-TTR-retinol 
triad is known as the retinol transport complex[95].  All components in the retinol 
transport complex benefit from molecular interactions with these partners.  The binding 
of retinol to RBP4 gives RBP4 a higher binding affinity for TTR[95].  TTR binding to 
RBP4 prevents glomerular filtration of RBP4 by the kidneys[96].  RBP4 binding to TTR 
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in turn significantly stabilizes the native tetramic state of TTR[29].  A paper by Kelly and 
White in 2001[97] showed that RBP binds both wild-type and L55P TTR in vitro and 
stabilized the tetrameric form of TTR.  Thus, RBP appeared to prevent disassembly of 
TTR into monomers, the key step in the TTR fibril formation pathway.  In addition, the 
authors showed that the presence of RBP slowed down amyloid fibril formation in vitro 
and enhanced small molecule inhibitor activity of fluflenamic acid and diclofenac.  
   
  
29 
 
Figure 7.  Retinol-binding protein–transthyretin (RBP-TTR) complex.  
The ribbon diagram shows the TTR tetramer (blue) bound to two RBP molecules (red).  
Each RBP molecule has one retinol molecule (yellow) bound inside its beta barrel 
structure.  White JT et al., PNAS (2001)[97].  Copyright (2001), National Academy of 
Sciences, U.S.A. 
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1.9 Research goal, hypothesis, and specific aims 
The goal of the research presented in this dissertation was to further understand 
the pathologic effect of soluble amyloidogenic forms of TTR on the heart and to explore 
the protective potential of several agents. 
We hypothesized that pre-fibrillar, oligomers of TTR would be cardiotoxic and 
that this cytotoxic effect contributed to cardiac amyloid pathology in ATTR amyloidosis 
(Figure 8).  Further, we postulated that this cardiotoxic effect could be inhibited by 
agents, namely diflunisal, doxycycline, Kiacta®, and RBP through interactions with 
native and non-native forms of TTR.  Specifically, we posited that soluble, aggregated 
TTR would be toxic to cultured cardiac cells, i.e. cause decreased cell survival and 
increased myocardial stress.  Using purified recombinantly-generated TTR proteins, we 
tested our hypothesis by creating amyloidogenic TTR oligomers in vitro, testing the 
effect of oligomeric TTR on cultured rat and human cardiac cells, and investigating the 
cell rescue potential of the proposed inhibitory agents.  
The specific aims of this research were as follows:  
Specific Aim 1:  To develop a method for reproducibly creating soluble amyloidogenic 
TTR in a time-efficient manner using physiological conditions. 
Specific Aim 2:  To treat cardiac cells (rat cardiomyoblasts, human iPSC-derived cardiac 
cells) with oligomeric, pre-fibrillar TTR and assess the cellular response both 
morphologically and chemically. 
Specific Aim 3:  To examine the potential of diflunisal, doxycycline, Kiacta®, and 
retinol-binding protein (RBP) to inhibit the cardiotoxic effect of TTR oligomers. 
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1.10 Significance 
The TTR-associated amyloidoses are a group of rare, but aggressive and fatal 
diseases with few treatment options available to patients.  While the clinical presentations 
in ATTR amyloidosis have been extensively described, little is known about the precise 
mechanism of the disease.  While the presence of amyloid deposits may cause 
mechanical disruption of cellular and tissue function, it is generally held that these are not 
the disease-causing entity.  Over the past ten years, research in the field has shifted from 
the tissue deposits to earlier stage forms of the amyloid protein and understanding the 
damaging impact of soluble, pre-fibrillar forms of TTR.  In the studies presented in this 
dissertation, the goal was to characterize the toxic effects of TTR oligomers using cell-
based models.  Furthermore, since both ATTRwt and ATTRm frequently feature 
infiltrative cardiomypathy and cardiac amyloid, we chose to study the effects of 
amyloidogenic forms of TTR on two cardiac cell types, rat cardiomyoblasts and human 
iPSC-derived cardiac embroid bodies (cEBs).  Results from these studies should further 
the present understanding of the pathobiology of ATTR amyloidosis as we believe the 
mechanism includes cardiotoxicity induced by pre-fibrillar forms of TTR. 
In addition to the incomplete understanding of disease mechanism, treatment 
options and efficacious therapies for patients with ATTR amyloidosis are lacking.  There 
is also a necessity for disease markers and prognostic indicators in ATTRwt amyloidosis, 
a disease that is particularly difficult to detect in the early stages.  These unmet needs 
prompted us to investigate several potential inhibitory agents, as well as study the nature 
of retinol-binding protein (RBP) in our TTR-amyloid patient population.  
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Figure 8.  TTR amyloid cascade hypothesis. 
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CHAPTER 2.  METHODS  
2.1 Chemicals and reagents 
All chemicals and reagents were of the highest grade available.  Phosphate 
buffered saline (PBS), methanol (MetOH), hydrogen peroxide (H2O2), dimethyl sulfoxide 
(DMSO), penicillin-streptomycin (Pen-Strep), L-glutamine, and ammonium persulfate 
(APS) were all purchased from Fisher Scientific (Fairlawn, NJ).  Gelatin, bovine serum 
albumin (BSA), Congo red, Thioflavin T, doxycycline hyclate, and LB broth were 
purchased from Sigma (St. Louis, MO).  Glutaraldehyde and diflunisal were purchased 
from MP Biomedicals (Santa Ana, CA).  Fetal bovine serum (FBS) was purchased from 
Atlanta Biologicals (Flowery Branch, GA).  Primary antibodies were purchased from 
DAKO (Troy, MI).  All secondary antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX).  Dulbecco’s modified Eagle’s medium (DMEM) was 
purchased from Corning (Corning, NY) and Tryp-LE from Invitrogen (Carlsbad, CA).  
Non-essential amino acids (NEAA) were obtained from CellGro (Corning, NY).  
Kiacta® was obtained from Piramal Healthcare Ltd. (Aurora, Ontario, Canada). 
2.2 Cell culture experiments 
H9C2 rat cardiomyoblasts (ATCC CRL-1446) were grown in 75 cm
2
 flasks 
containing DMEM supplemented with 10% FBS, 100 units/mL Pen-Strep, and 2 mM L-
glutamine.  Cells were cultured at 37 °C and 5% CO2.  To passage confluent cells, 
medium was aspirated off and cells were washed with PBS.  Cells were detached with the 
addition of 1 mL Tryp-LE and this was followed with a 5 minute incubation at 37 °C.  
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When detachment was complete, 7 mL of fresh medium was added and the cells were 
transferred into new T75 flasks at a 1:4 or 1:8 ratio (mL cell suspension: mL medium).  
2.3 Generation of cardiac embroid bodies from induced pluripotent stem cells 
Human cardiac embroid bodies (cEBs) were derived from induced pluripotent 
stem cells (iPSCs).  The iPSCs were from two sources, commercially obtained dermal 
fibroblasts from a 27-year old heterozygous for the TTR-L55P mutation, and blood 
mononuclear cells (MNCs) from a healthy individual (labeled as BU6). 
A 7-day protocol was used to differentiate the iPSCs into cardiac cells.  On day 0, 
iPSCs that had been grown up to 80% confluence in 6-well plates were washed with PBS, 
treated with 500 μL dispase for 2 minutes, and washed again with PBS.  One mL of cEB 
growth medium (DMEM, 20% FBS, 1% NEAA, 1% L-glutamine, 100 mM 2-
mercaptoethanol, 2 ng BMP4, 1 μM RhoK) was added to each well and cells were 
dissociated using a cell scraper.  The cell/medium mixture was transferred to 35 mm 
diameter dishes (Stemcell Technologies, Vancouver, Canada) and brought to a final 
volume of 2 mL medium per dish.  After 24 hours of incubation at 37 °C, low O2 and 5% 
CO2 (day 1), the cells were switched into cEB medium containing BMP4, ActA and 
bFGF.  Medium was refreshed again on day 4.  On day 7, 12-well plates were prepared 
by coating them with 0.1% gelatin in H2O for 10 minutes.  The cEBs were collected from 
the 35mm dishes, washed with PBS, transferred into the coated 12-well plates, and 
supplemented with cEB medium containing no cytokines. 
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2.4 Cell viability assay 
To assess cell viability, we used the ApoTox-Glo™ Triplex Assay (Promega, 
Madison, WI).  This assay detects live cells by using their protease activity to cleave the 
fluorogenic substrate, glycyl-phenylalanyl-aminofluorocoumarin (GF-AFC).  The 
substrate is taken up by intact cells and cleaved by cellular proteases.  This enzymatic 
activity generates free AFC with a fluorescent signal that has an excitation wavelength at 
400 nm and emission wavelength at 505 nm.  Twenty μL of the GF-AFC compound was 
added to wells in a black 96-well plate and incubated for 30 minutes at 37 °C, 5% CO2.  
Fluorescence was measured at 400nm (excitation) and 505nm (emission). 
2.5 Cross-linking protocol 
Ten μL of 25% glutaraldehyde was added to 100 μL TTR protein sample (0.4 
mg/mL) and incubated at room temperature for 3 minutes.  The reaction was quenched by 
adding 5 μL of 7% (w/v) NaBH4 in 0.1 M NaOH.  Cross-linked samples were analyzed 
by SDS-PAGE electrophoresis as described in 2.8.  
2.6 Immunohistochemistry and Congo red staining  
Paraffin blocks containing the tissue of interest were frozen overnight and placed 
in a shallow bath of ammonia water immediately before sectioning.  Using a microtome, 
sections were cut to 5 μm or 8 μm in thickness for imunohistochemical or Congo red 
staining, respectively.  Sections cut from the paraffin block as a ‘ribbon’ were gently 
placed on the water surface in the bath and maintained at 45 °C.  Using tweezers, sections 
were separated from one another and floated onto glass barrier microscope slides 
(Biogenex, San Ramon, CA) or positively charged slides for Congo red staining.  Slides 
  
36 
containing the sections were heated at 65 °C in an oven for at least one hour; this allowed 
the tissue to adhere to the glass surface and prevented loss of sections during the 
histologic treatment process.  Sections were deparaffinized in two changes of xylene (4 
minutes each) and subsequently hydrated in two changes of 100% ethyl alcohol and 95% 
ethyl alcohol.  Following three rinses in dH2O, slides were placed in an H2O2/MetOH 
solution (200 mL MetOH, 50 mL 3% H2O2) for 10 minutes. 
To unmask antigen for better recognition by the antibodies, slides were placed in 
Antigen retrieval Citra plus solution (Biogenex) and heated to 95 C for 8 minutes.  
Slides were cooled to room temperature for 20 minutes and placed in an automated 
immunohistochemical staining instrument (DAKO).  To prevent drying, slides were 
immediately covered with wash buffer (DAKO).  
The autostainer was loaded with appropriate staining solutions.  After the program 
run, slides were counterstained with Harris-modified hematoxylin (Harris-modified 
hematoxylin with 1% glacial acetic acid) rinsed, dipped in 0.25% acid alcohol (0.25% 
HCl in 70% ethyl alcohol) two times and quickly washed under running tap water.  This 
was followed by a rinse in 1% ammonium water for 20 seconds; dehydration of the 
sections was accomplished with 95% and 100% ethanol, and lastly xylene.  Sections of 
the slides were protected with coverslips applied using Permount mounting medium 
(Fisher). 
2.7 Fluorescent microscopy 
H9C2 cells (3000 cells/well) were plated onto sterile glass coverslips pre-coated 
with 0.2% gelatin in 6-well plates.  The cells were allowed to adhere and settle onto the 
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coverslips for 24 hours at 37 °C and 5% CO2, prior to treatment.  Following experimental 
treatment protocols of 72 hours, media was aspirated and cells were washed in three 
changes of PBS.  Using a 4% formaldehyde solution, cells were fixed for 15 minutes at 
room temperature, washed three times with PBS, and permeabilized with 0.1% Triton-X 
for 5 minutes.  Following fixation and permeabilization, cells were blocked in 3% BSA 
overnight at room temperature.  The next day, cells were washed four times with PBS 
and incubated with a 1:200 dilution in PBS of primary antibody (polyclonal goat-anti-
human TTR) for one hour at 4 C.  The antibody solution was removed and cells were 
again washed three times with PBS.  Secondary antibody (polyclonal donkey-anti-goat-
IgG, FITC-labeled) at a 1:100 dilution in PBS was added to the cells which were then 
incubated for another hour at 4 C in the dark. 
For visualization of actin filaments within the cells, coverslips were removed 
from the 6-well plate, placed in a humid chamber, and stained with 100 nM rhodamine 
phalloidin (Cytoskeleton Inc., Denver, CO) for 30 minutes in the dark at room 
temperature.  Following three final washes with PBS, the coverslips were counterstained 
for DNA and mounted onto microscope slides using slow-fade DAPI mountant (Life 
Technologies, Carlsbad, CA).  An Olympus BX60 fluorescent microscope was used for 
visualization; picture images were taken using a QImaging Retiga 2000R camera and 
software.  
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2.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
2.8.1. Manual gel electrophoresis 
Protein samples were mixed at a 1:1 dilution with loading buffer (50 mM tris-HCl 
pH6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue) supplemented with 1% 2-
mercaptoethanol.  Samples were boiled for 5 minutes, briefly spun at 10,000 rpm, and 
loaded into 1 mm thick 10% SDS-PAGE gels with 5% stacking gels for electrophoretic 
separation.  Protein standards (Spectra Broad Range Protein Ladder, Pierce) were run in 
parallel for reference.  
2.8.2. Automated (Pharmacia PHAST system) gel electrophoresis 
For protein separation on precast 4-15% gradient gels, the automated Phast 
System (GE, Fairfield, CT) was used.  Precast gels were placed in the system, making 
sure to pipette 90 µL H2O onto the surface in order to avoid air bubbles.  Next, SDS 
buffer strips were placed on either end of the gel to prevent dehydration during 
electrophoresis.  Protein samples were mixed with 2x loading buffer at a 1:1 ratio and 
boiled as described in 2.8.1.  One µL samples were loaded into one of six wells on a 
plastic comb as quickly as possible to avoid evaporation.  
2.9 Western blot analysis 
For Western blot analysis, proteins were initially separated by SDS-PAGE and 
subsequently transferred onto a nitrocellulose membrane using a wet transfer method that 
proceeded overnight in transfer buffer (1.66 g tris base, 7.2g glycine, 100 mL MetOH, 
final volume 500 mL, pH 8.4) at 4C (BioRad).  The next day, the membrane was soaked 
in blocking buffer (10% non-fat dried milk in TBST) for 1 hour at room temperature, 
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washed with TBST, and incubated with primary antibody in 5% milk for two hours at 
room temperature.  For TTR detection, a polyclonal rabbit anti-human TTR antibody 
(DAKO) was used at 1:20,000 dilution in 2.5% BSA in PBS.  A mouse anti-human 
polyclonal RBP antibody (Santa Cruz) at 1:1000 dilution in 2.5% BSA in PBS was used 
for RBP analyses.  Following three TBST washes of the membrane, the appropriate 
secondary antibody, either 1:10,000 goat anti-rabbit IgG-HRP or 1:10,000 goat anti- 
mouse IgG-HRP, was added for detection of TTR or RBP, respectively.  After a 1 hour 
incubation, blots were washed and developed using the ECL Plus Western blotting 
detection system (Pierce). 
2.10 Congo red shift assay 
To assess aggregation of TTR, a Congo red shift assay was performed.  An initial 
stock solution of 1 mM Congo red in 40% EtOH was used in these studies.  TTR protein 
samples that had been incubated for one week at 80 C in 1.5 mL Eppendorf tubes were 
spun down at 25,000 x g for 10 min.  Supernatant was discarded and the pellet was 
resuspended in 10 μM Congo red working solution (10 μM Congo red, 5mM KH2PO4, 
150 mM NaCl, pH 7.5).  Samples were transferred into cuvettes and absorbances were 
recorded at 477 nm and 540 nm in a Cary 300 UV-Vis spectrophotometer (Agilent).  A 
red shift, i.e. a shift towards the longer wavelength end of the spectrum, indicates that the 
dye is binding to protein and provides evidence for the presence of pre-fibrillar 
aggregates and/or amyloid fibrils[6]. 
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2.11 Thioflavin T analysis 
TTR protein (0.4 mg/mL) was heated to 80 C over the course of several hours.  
At various time points, the amount of soluble TTR aggregates was assessed by thioflavin 
T (ThT) fluorescence measurements.  ThT was dissolved in 100% EtOH at a 
concentration of 10 mM and filtered through a 0.22 µm syringe filter to remove any 
particulates.  The solution was diluted in PBS to make a stock solution of 20 µM ThT.  
For ThT fluorescence measurements, 100 µL of TTR sample was combined with 100 µL 
ThT stock solution; the final ThT concentration was 10 µM.  The 200 µL mixture was 
transferred into a black 96-well plate and ThT fluorescence was measured in a 
FluoroMax spectrofluorometer (Horiba Jobin, Kyoto, Japan) at an excitation wavelength 
of 440 nm and emission wavelength of 482 nm using a 5 nm slit width.  Samples were 
measured in triplicate and measurements were normalized to a blank solution of ThT. 
2.12 Expression and purification of recombinant transthyretin protein 
Recombinant TTR proteins with N-terminal 6-histidine-tags were expressed in 
E.coli M15 [pREP4] cells using the pQE30 expression vector[98].  To grow up the E.coli, 
flasks of LB broth (each 500 mL) were autoclaved, supplemented with 12.5 mg 
kanamycin and 50 mg ampicillin, inoculated with a single isolated bacterial colony, and 
cultured overnight at 225 rpm at 37 C. 
The following day, 0.5 liters of LB broth was inoculated and incubated 37 C 
with shaking at 225 rpm.  This was continued until the broth solution exhibited an optical 
density (OD) of 0.6 at 600 nm.  Expression of rTTR was induced by addition of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1 mM.  Following 4 hours 
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of incubation at 37 C, the media was centrifuged in an SLA-1500 rotor at 6,000 rpm for 
20 minutes at 4 C. 
An immobilized-metal ion affinity column (IMAC) method was used to purify the 
bacterially-generated TTR.  Once the cells were pelleted, the supernatant was discarded; 
pellets were resuspended in IMAC cell lysis buffer (50 mM NaH2PO4 2 H2O, 300 mM 
NaCl, 10 mM imidazole, pH 8.0) at 3 mL per gram wet weight.  Solutions were 
supplemented with lysozyme at 1 mg/mL and incubated on ice for 30 minutes.  
Following incubation, the cells were sonicated in 15 minute intervals until the solution 
appeared clear and had changed to a darker brown color, indicating cell lysis.  This 
sonication procedure was performed on ice to prevent overheating.  The lysed cell 
mixture was centrifuged in an SS-34 rotor at 9,000 rpm for 30 minutes at 4 C.  The 
supernatant was filtered through 0.22 µm syringe-filters. 
A 3 mL IMAC Ni-NTA (nickel-nitrilotriacetic acid) sepharose column (Qiagen) 
was prepared and equilibrated in several rinses of PBS.  Up to 20 mL of cleared lysate 
was allowed to run through the column, allowing the rTTR protein to bind to the nickel 
resin through its 6 histidine tag.  The column was rinsed with IMAC wash buffer (50 mM 
NaH2PO4 2 H2O, 300 mM NaCl, 20 mM imidazole, pH 8.0) until OD280 nm was zero.  
Recombinant TTR protein was eluted from the column using IMAC elution buffer (50 
mM NaH2PO4 2 H2O, 300 mM NaCl, 250 mM imidazole, pH 8.0); fractions with an 
OD280 nm > 0.1 were collected and pooled.  The pooled fractions containing rTTR protein 
were dialyzed into PBS using 7,000 MWCO Slide-A-Lyzer cassettes (Thermo Scientific) 
and the PBS was changed every 30 minutes for at least 2 hours. 
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Protein concentration was determined by measuring the absorbance at 280 nm and 
calculating with the following formula:  A = ε λ C, where A is absorbance at OD280 nm,  
ε is the extinction coefficient for TTR = 77,600 M-1 cm-1[99], λ is the cell length of the 
cuvette, and C is the molar concentration of the rTTR protein solution.  Protein was 
immediately flash frozen in a mixture of dry ice and acetone, and transferred to a -150 C 
freezer for long-term storage. 
2.13 Serum retinol-binding protein 4 measurement by enzyme-linked 
immunosorbent assay 
To measure circulating levels of RBP4 in patient serum samples, a sandwich 
enzyme-linked immunosorbent assay (ELISA) was developed.  High-binding, flat bottom 
96-well plates (Nunc) were coated with 1:500 mouse anti-human RBP4 monoclonal 
antibody (R&D) and stored overnight at 4 C.  The coating antibody was removed and 
plates were washed three times with PBS containing 0.1% tween using a Biotek ELx405 
automated plate washer.  Plate wells were blocked with 1% BSA for one hour at room 
temperature and washed three times with PBS containing 0.1% tween-20.  RBP4 standard 
protein (R&D) and serum dilutions (1:100,000) were prepared in 0.2% BSA, 0.25% 
tween and loaded onto plates; all samples were run in triplicate.  The plates were 
incubated for 2 hours at room temperature with shaking at 500 rpm.  Following another 
wash, 1:4,500 biotinylated polyclonal mouse anti-human RBP4 antibody was added and 
plates were incubated for 2 hours at room temperature with shaking at 500 rpm.  The 
plates were washed and streptavidin-HRP was added; a 30 minute incubation at room 
temperature with shaking at 500 rpm followed.  After another wash step, TMB substrate 
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was added and plates were incubated in the dark at room temperature for 25 minutes.  
This reaction was quenched with 1.5 N H2SO4 and plates were read at 465 nm and 590nm 
(background) using a Biotek ELx800 plate reader.  Background values were subtracted 
from 465 nm measurements and triplicate values were averaged.  Data were analyzed 
using unpaired two-tailed t-tests with Mann-Whitney U test.  Statistical significance was 
p-value < 0.05. 
2.14 RNA isolation and quantitative polymerase chain reaction 
Cells, plated in a 12-well plate, were washed three times with PBS and 350 µL 
RLT (Qiagen) lysis buffer was added to each well.  The cell lysate solutions were 
homogenized and transferred to 2 mL conical bottom sample tubes.  The tubes were 
loaded into a Qiacube automated RNA isolation system and RNA was purified from cell 
lysates using the RNeasy Plus Mini kit (Qiagen).  Isolated RNA was removed from the 
Qiacube and quantified prior to cDNA synthesis.  cDNA was synthesized from 250 ng of 
RNA template using the QuantiTect Reverse Transcription kit (Qiagen) according to the 
manufacturer instructions.  Briefly, genomic DNA (gDNA) was removed prior to cDNA 
synthesis by addition of gDNA removal buffer to 250 ng RNA.  The mixture was 
incubated at 42 C for 2 minutes.  Immediately after gDNA removal, reverse 
transcription master mix containing reverse transcriptase and primers (obtained from the 
Dr. George Murphy Laboratory, see Table S1 for sequences) was added to the reaction 
tubes.  The reaction was incubated for 15 minutes at 42 C and inactivated at 95 C.  
For qPCR, SYBR® Green PCR Master Mix (Applied Biosystems) was mixed with the 
appropriate primers (Table S1) and added to 7.25 ng cDNA in 96-well reaction plates.  
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The plates were loaded into a StepOne Real-time PCR machine (Applied Biosystems).  
All samples were run in duplicate and normalized to GAPDH.  The Student’s t-test 
statistical analysis was used to determine significance.  Statistical significance was  
p-value < 0.05. 
2.15 Circular dichroism spectroscopy 
Secondary structure and folding of proteins was studied using a Jasco J-815 
spectropolarimeter.  Briefly, protein solutions were prepared at 0.4 mg/mL in PBS and 
transferred to a 0.1 cm quartz cell.  Far-UV spectra were recorded at 25 C in triplicate 
with monitoring between 200 and 250nm (far UV) using a 0.1 nm bandwidth.  To assess 
changes in the secondary protein structure during thermal denaturation or melting, the 
sample was heated from 25 C to 98 C at a rate of 1 C /min and the CD signal was 
recorded at 213 nm every minute.  Subsequent sample cooling from 98 C to 25 C was 
also recorded and analyzed.  Data were normalized to protein size (residue number) and 
concentration, and plotted as mean residue molar ellipticity (MRE). 
2.16 Study populations 
Patient sera, tissue samples, and clinical data were obtained from the Boston 
University Amyloidosis Center repository with the approval of the Institutional Review 
Board at the Boston University Medical Campus in accordance with the Declaration of 
Helsinki.  Patient groups included patients with ATTRm, ATTRwt, or AL amyloidosis.  
Inclusion criteria for the patient study groups were male gender, aged 60 years or older, 
and triglyceride levels < 200 mg/dL.  A triglyceride cut-off value of 200 mg/dL was 
chosen based on previous reports showing a correlation of increased RBP4 levels to 
  
45 
obesity[100].  Control sera from healthy individuals, which were age- and gender-
matched to our patient groups, were obtained from BioReclamation (Westbury, NY).  
Since BMI values were not available on all study patients, triglyceride levels were 
considered in order to rule out a potential confounding variable.  A diagnosis of TTR 
amyloidosis was established by Congo red histology and immunohistochemistry or mass 
spectrometric analysis, isoelectric focusing (IEF), and genetic testing by DNA 
sequencing.  AL amyloidosis was confirmed by bone marrow biopsy and the presence of 
a monoclonal immunoglobulin light chain in the serum and/or urine. 
A patient was considered to have cardiomyopathy or cardiac involvement when 
presenting with an abnormal echocardiogram, increased left ventricular mass (LVM), 
lowered ejection fraction (EF), and left ventricular wall thickening > 12 mm.  Patient 
laboratory data that was evaluated included brain natriuretic peptide (BNP), cardiac 
troponin (cTn-I), VO2 (metabolic stress test), and uric acid.  These values were obtained 
from the Boston University Amyloidosis Center clinical database. 
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CHAPTER 3.  IN VITRO GENERATION OF AMYLOIDOGENIC 
TRANSTHYRETIN OLIGOMERS UNDER PHYSIOLOGIC CONDITIONS 
 3.1 Introduction 
As was previously described, there has been an increasing focus on the pre-
fibrillar soluble TTR oligomers believed to be the toxic species in amyloidosis; this is in 
contrast to the previously held belief that the mature fibrils were the sole cause of disease 
manifestations[20].  The aim of our studies was to investigate the effect of TTR pre-
fibrillar species on cells.  Our plan was to examine cellular viability following direct 
exposure of cells to soluble amyloidogenic forms of TTR.  Thus, we needed to develop a 
method that would allow us to generate oligomeric TTR under conditions that were close 
to physiologic and within a reasonable time frame.  In addition, it would also be ideal to 
minimize manipulation or alteration of the TTR proteins that were being used.  
Previously reported TTR fibril formation assays all presented major disadvantages or 
were not suitable for our planned cell-based studies.  One method that has been used 
extensively generates TTR oligomers and amyloid fibrils under acidic conditions (pH ≤ 
4.5)[39], [47], [101].  This protocol was developed for in vitro biochemical and 
biophysical analyses of TTR aggregates and fibrils.  For our studies, this method was not 
an option as treating the cells with acidic solutions of protein would undoubtedly cause 
damage unrelated to amyloidogenic TTR. 
Some research groups have attempted to use physiological conditions for TTR 
aggregate and fibril formation.  Sousa et al.[102] incubated TTR-L55P protein at 37 C 
and pH 7.0 for 15 days; the authors of this study observed fibrils by transmission electron 
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microscopy (TEM) on day 15 and aggregates after just 24 hours.  Moreover, Azevedo et 
al. observed TTR-A25T fibril formation after 15 days at pH 7.3 and 37 C [43].  
Based on these studies, our aim was to create an assay at a neutral pH, i.e. pH 7.4, using 
thermal denaturation (80 C) to form aggregates in a shorter time interval than the 
previously described methods. 
Our interest in understanding how TTR amyloid affects the heart led us to study 
TTR proteins that have a strong association with cardiac amyloid disease and are reported 
to be most amyloidogenic based on in vitro studies. In this dissertation research, we 
focused on the wild-type protein and three TTR variants L55P, V30A, and V122I (Table 
1). 
3.2 Thermal denaturation forms high molecular weight transthyretin aggregates 
The first step in our studies was to produce each TTR protein (wt, L55P, V30A, 
V122I) in abundant amounts and purified to homogeneity.  It was also critical to create 
proteins that exhibited structural characteristics identical to the native protein.  
Expression of rTTR protein was accomplished using an E.coli bacterial system 
established in our laboratory[98] and purification of the histidine-tagged protein was 
performed using immobilized metal ion column chromatography (IMAC), as was 
described in Chapter 2. 
The purity of recombinant proteins was assessed by SDS-PAGE run under 
reducing conditions; a representative example is shown in Figure 9a.  Protein staining 
with Coomassie blue indicated a predominant species with an apparent molecular weight 
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of 14 kD and a minor one at 55 kD; these results were as expected for monomeric and 
tetrameric TTR, respectively. 
Confirmation of native conformation, i.e. proper folding and correct secondary 
structure, was analyzed by circular dichroism spectroscopy (CD).  Far UV (195-240 nm) 
spectra were recorded and an example demonstrating the analysis is shown in Figure 9b.  
The measurements indicated that rTTR (wt shown as an example) protein was properly 
folded and displayed high beta sheet content, as is expected in neutral PBS buffer. 
Having confirmed the purity and structural integrity of the rTTR proteins, we 
proceeded with our method development (Figure 10) for generating TTR oligomers.  
Solutions of TTR at 0.4 mg/mL in PBS (pH 7.4) were freshly prepared prior to each 
experiment.  This concentration of TTR was chosen because it represents a physiologic 
level; the normal range for serum-circulating TTR is 0.2  – 0.45 mg/mL[26], [27].  
Unfolding and aggregation of the protein samples were induced using a thermal 
denaturation assay in which the proteins were incubated at 80 °C.  After 0, 24, 48, 120 or 
144 hours of incubation, the proteins were cross-linked with 25% glutaraldehyde and run 
on 10% SDS-PAGE gels to assess the aggregated state of the protein.  
Representative images of the gels showing results obtained for wt and L55P TTR, 
the most unstable mutant of the three studied variants, are illustrated in Figure 11.  The 
results showed that L55P rapidly aggregated into high molecular weight (HMW) soluble 
aggregates with an apparent molecular weight > 260 kD.  Within 24 hours of the 80 °C 
treatment, there was little evidence of tetrameric TTR providing evidence for dissociation 
of the native protein.  By 48 hours at 80 °C, a decrease in the HMW species was 
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observed on the gels and this suggested that the aggregated forms of TTR had become 
insoluble and were precipitating out of solution. 
In contrast to L55P TTR, the wt tetramer, as expected, proved to be more resistant 
to the heat denaturation process.  Results from the electrophoretic analysis suggested that 
a minimal amount of aggregated (HMW) wt TTR was formed by 24 hours, but thereafter 
was present and remained visible for several days.  This is in contrast to the L55P HMW 
species which were no longer observed by 48 hours, most likely due to formation of large 
insoluble aggregates.  When compared to L55P TTR, the wt protein, overall, showed 
much less loss of tetramer or native state protein in the heat denaturation process during 
the 144 hour course of incubation.  These data provide evidence consistent with the 
literature that wt TTR is structurally more stable than L55P[47].   
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Figure 9.  SDS-PAGE and far-UV circular dichroism of wild-type recombinant 
TTR. 
(a) SDS-PAGE gel of wt rTTR protein with a predominant band at 14 kD (monomer) and 
minor band at 55 kD (tetramer) on a 10% acrylamide reducing gel.  The gel was stained 
with Coomassie blue dye.  (b) Far UV spectrum recorded between 195 and 240 nm in 
PBS at room temperature showing expected folding and secondary structure (high beta 
sheet content) of the wt rTTR protein. 
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Figure 10.  Schema for in vitro formation and analyses of TTR oligomers. 
The experimental design for development and validation of our thermal denaturation 
assay is shown.  TTR protein at 0.2 mg/mL in PBS was incubated at 80 C.  Aliquots of 
the protein solution were removed at timed intervals (0, 4, 24, 48, 72, 144 hours) for 
analyses by 1) cross-linking proteins and SDS-PAGE, 2) Congo red shift, and 3) 
Thioflavin T assay. 
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Figure 11.  Formation of high molecular weight aggregates by 24 hours at 80 °C.  
Aggregates formed in the thermal denaturation assay were analyzed by cross-linking and 
SDS-PAGE.  The results with wt and L55P TTR proteins are shown in the left and right 
panels, respectively.  In each gel, a molecular weight ladder was run in the first left lane; 
standard proteins had apparent molecular weights of 10, 15, 25, 35, 40, 50, 70, 100, 140, 
260 kD shown from the bottom to the top of the gel.  From left to right on both gels, 
samples of TTR removed during the 80 °C incubation at times 0, 24, 48, 120, and 144 
hours are shown.  The apparent molecular weights of tetrameric or native TTR and high 
molecular weight species were observed at 55 kD and > 260 kD, respectively.  Protein 
samples were run on 10% SDS-PAGE gels and visualized with Coomassie blue. 
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3.3 High molecular weight aggregates formed are pre-fibrillar oligomers  
Once it was established that HMW TTR aggregates could be successfully 
generated with our heat denaturation protocol, we wished to characterize these species 
and confirm that they were in fact intermediates on pathway to amyloid fibril formation.  
To assess the amyloidogenicity of the aggregates, we used Congo red, a diazo dye 
described in Chapter 1.  As mentioned, this is a dye that has the unique ability to 
intercalate between the beta sheets of amyloid.  Congo red can be used as a histologic 
stain to detect the presence of amyloid fibrils in tissues or as an indicator of aggregates in 
an absorbance shift assay[6].  In the latter assay, a solution containing amyloid 
aggregates can be assessed by observing a difference (spectral shift) in the wavelengths at 
maximum absorbance (λmax) of the free and amyloid-bound dye.  This assay is a common 
way to measure amyloid protein aggregation. 
Wild-type, V30A, and V122I TTR proteins were incubated for one week at 80 °C 
and subsequently mixed with Congo red.  The absorbance spectra were recorded between 
300 and 700 nm.  As can be seen in Figure 12, a red shift in λmax was observed for each 
of the three TTR proteins compared to the Congo red control.  The λmax of the free dye is 
486.0 nm; spectral shifts to 487.0, 491.0, and 492.0 nm occurred in the wt, V30A, and 
V122I TTR samples, respectively.  These data presented evidence supporting the 
formation of amyloidogenic aggregates in the TTR thermal denaturation assay.  As 
expected, the wild-type TTR exhibited a minimal red shift indicating lower levels of 
aggregate formation.  Interestingly, V122I TTR showed the largest red shift indicating 
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that over the course of seven days this protein formed more amyloidogenic species 
compared to the other variants tested.  
To confirm that the L55P TTR HMW aggregates were on pathway to form 
amyloid, we used Thioflavin T, a benzothiazole dye which also has been used to detect 
amyloid[7].  We chose to use this assay, as opposed to the previously described Congo 
red shift assay, because we anticipated that L55P, a very unstable variant, would form 
aggregates and oligomers very early in the thermal denaturation process.  Since the 
Congo red shift assay requires a significant amount of aggregation for detection, we 
chose to use the Thioflavin T assay which can detect earlier stage (within hours) soluble 
oligomer formation.  L55P TTR protein was incubated at 80 °C for approximately 4 
hours.  Measurements of ThT flurorescence on TTR samples removed at 0, 45, 60, 120, 
and 200 minutes during the thermal denaturation assay are shown in Figure 13.  ThT 
fluorescence increased within one hour of heating and indicated that HMW TTR species 
were being formed.  These data indicated that the HMW aggregates seen by SDS-PAGE 
analysis (Figure 11) were amyloidogenic in nature. 
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Figure 12.  Congo red spectral shift analysis of thermally denatured TTR samples. 
The absorbances of wt, V30A, and V122I TTR solutions (1mg/ml), incubated for one 
week at 80 °C, were measured in the wavelength range between 450 and 550 nm.  The 
final Congo red concentration in each sample was 10 μM.  Measurements were made in a 
1 cm cuvette.  A control solution containing only Congo red yielded a maximum 
absorbance at a wavelength (λmax) of 468.0 which is consistent with the reported value of 
the free dye.  All three TTR proteins showed spectra with shifts in the λmax of Congo red.  
Values for the λmax of individual proteins and Congo red alone are shown in the table.   
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Figure 13.  ThT fluorescence analysis of thermally denatured TTR-L55P. 
The L55P TTR protein (0.4 mg/mL) was incubated at 80 °C for 200 minutes.  Aliquots 
were collected from the incubation at 0, 45, 60, 120, and 200 minutes and mixed with 
ThT (final concentration of 10 μM ThT), then analyzed for fluorescent output.  
Fluorescence was measured at excitation and emission wavelengths of 440 and 482 nm, 
respectively.  Samples were all measured in triplicate; each datapoint shown on the graph 
represents the mean of the triplicate readings along with standard error bars of variation.  
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3.4 Summary and conclusions  
In this chapter, we have detailed the development of a reproducible method to 
create soluble, high molecular weight aggregates of wt and variant TTR proteins.  We 
have provided evidence showing that heat denaturation at 80 °C is a rapid and effective 
means of creating oligomeric forms of TTR that are precursors of amyloid fibrils. 
Initially, we used SDS-PAGE and CD analyses to verify the generation of 
homogeneous preparations of recombinant wt and variant TTR proteins that were 
properly folded and exhibited native structural characteristics.  Focusing on wt and L55P, 
we showed by glutaraldehyde cross-linking and SDS-PAGE analysis that thermal 
denaturation at 80 °C yielded high molecular weight TTR aggregates.  The 
amyloidogenic TTR variants, V30A and V122I, were also studied in these experiments 
and results will be detailed in Chapter 4. 
We conclude from the data presented in this section that 80 °C treatment of TTR 
under physiologic conditions of concentration (0.2 mg/mL), salt (PBS), and pH (7.4) 
generates amyloidogenic TTR aggregates by 4 hours.  In addition, this is a reproducible 
and time efficient assay that will be appropriate for use in the planned cell-based studies 
undertaken to gain a fuller understanding of the effects of amyloidogenic TTR species on 
cardiac cell viability.
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CHAPTER 4.  CARDIAC CELL RESPONSE TO TRANSTHYRETIN 
OLIGOMERS 
4.1 Introduction 
With an established method in place to create amyloidogenic TTR oligomers, the 
next step was to examine the effect of these on cardiac cells.  The goal was to measure 
the effect of TTR oligomers on cell viability.  As was detailed in Chapter 3, the thermal 
denaturation studies were performed in a time interval of 144 hours; however, oligomer 
formation was observed as early as 24 hours.  In designing the cell-based studies, we 
specifically wanted to focus on earlier stage oligomers for several reasons.  Previous 
studies had suggested that earlier, smaller oligomeric forms of TTR were cytotoxic 
compared to larger aggregates and pre-fibrillar species, which elicited a far less damaging 
response.  For example, Sörgjerd et al. reported that only small TTR oligomers > 250 kD 
but < 1000 kD were toxic to SH-SY5Y neuroblastoma cells as measured in an MTT 
assay.  Moreover, the authors demonstrated that TTR aggregates > 1000 kD were 
significantly less toxic[20].  Findings published by Krishnan et al. using the prion-
determining region of yeast Sup35 similarly concluded that earlier stage oligomers were 
the toxic entities[103].  These previous findings, taken together with our SDS-PAGE 
results described in Chapter 3, led us to focus our studies on TTR oligomers formed in 
the initial four hours of thermal denaturation at 80 °C.  
There have been numerous studies that have previously reported a toxic effect of 
small soluble TTR oligomers on cells.  However, a majority of these investigations have 
focused on FAP-related TTR variants and were almost exclusively limited to studies 
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using neuronal cell lines as model systems.  For instance, pre-fibrillar TTR-V30M 
oligomers were shown to be cytotoxic to the IMR-32 neuroblastoma[104] and SH-SY5Y 
cells[105].  The goal of the studies presented in this dissertation was to further understand 
cardiac amyloid diseases associated with TTR.  To this end, we chose to use TTR 
proteins linked to major cardiac involvement featuring cardiomyopathy and sought to 
establish a cardiac cell-based model for study of these cardiac amyloidoses. 
  Specifically, we opted to study wild-type TTR associated with age-related or 
senile systemic amyloidosis, and three TTR variants, L55P, V30A, and V122I, 
responsible for familial cardiac amyloidosis.  Studies of these variants, particularly in 
cardiac cell systems, are limited.  Two recent reports examined TTR-V122I cell toxicity 
in experiments with human cardiomyocytes.  However, the TTR to which the cells were 
exposed was never characterized and it is unclear whether the protein was in the native or 
an aggregated state[106], [107].  The TTR-V30A variant has been shown to cause 
cytotoxicity in neuroblastoma cells[33], [48].  Sousa et al. demonstrated a cytotoxic 
effect of L55P aggregates in transgenic mice[108].  In addition, neurotoxicity due to 
L55P aggregates was observed in SH-SY5Y neuroblastoma[109] and rat Schwannoma 
(RN22) cells[110].  
To establish a cell model that would allow us to gain insight into TTR-associated 
cardiac amyloid pathology, we initially chose to use rat cardiomyoblasts (H9C2).  This is 
a cell line that has been used extensively to study cytotoxicity and cell viability, and is 
considered a most stable and reliable cardiac cell model[111]–[114].  A second model 
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system that was utilized our subsequent studies consisted of human cardiac embroid 
bodies (cEBs) differentiated from patient-derived iPSCs.  
For comparison to TTR, we chose to use bovine serum albumin (BSA) as a 
control protein in all studies.  BSA is a globular, non-amyloidogenic protein that is 
approximately 66 kD, a size similar to tetrameric TTR (55 kD).  BSA, as a protein 
control, would allow us more confidence in attributing effects from oligomeric TTR to 
the amyloidogenic species and not merely to non-specific aggregates. 
4.2 Some aggregated forms of transthyretin are toxic to rat cardiac cells 
Early stage oligomers were formed using the thermal denaturation assay in which 
a physiologic concentration (0.4 mg/mL) of TTR in PBS at pH 7.4 was heated at 80 °C 
for 4 hours.  Following respective 0 or 4 hour incubations, samples were cross-linked in 
25% glutaraldehyde, separated on 10% SDS-PAGE gels, and stained with Coomassie 
blue.  As can be seen in Figure 14a, the results for wt TTR showed a loss of tetramer 
content (T) and slight increase in intensity of the monomeric band (M) after the 4-hour 
thermal denaturation treatment; this was likely due to the molecular destabilization of the 
tetramer with concomitant dissociation to monomer.  In contrast, native TTR-L55P 
dissociated rapidly and aggregated into HMW oligomers (H) within 4 hours of the 80 °C 
treatment.  Very little monomer was observed in the heated sample, but an intensely 
stained protein band was noted at the top of the gel and indicated that aggregated forms 
of TTR (H) were present.  TTR-V30A and -V122I both showed an increase in 
monomeric content after thermal denaturation, as well some HMW oligomer formation 
(H).  Unlike the wt and L55P samples, there was an increased appearance of dimeric TTR 
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(D) in the heated V30A and V122I samples consistent with the occurrence of tetramer 
dissociation.  Interestingly, a 4-hour heat treatment of the BSA (B) control protein 
appeared to induce aggregation and loss of the native protein (Figure 14b).  The loss of 
the 66 kD protein (B) and appearance of a strongly intense protein band at the top of the 
gel (H) indicated thermally-induced denaturation and aggregation of BSA. 
H9C2 cells grown to confluence or an approximate density of 20,000 cells/well 
were exposed to untreated (80 °C for 0 hours) or heat-denatured (80 °C for 4 hours) TTR 
protein samples; cell-based testing included the four TTR proteins (wt, L55P, V30A, and 
V122I), BSA as a control protein of similar size to native TTR, and staurosporine as a 
positive indicator of apoptosis[115], [116].  Protein samples (0.4 mg/mL) were each 
added to the cardiomyoblast cells at a 1:1 ratio with complete medium; thus, cells were 
treated with TTR at a final concentration of 0.2 mg/mL, a representative level of the 
protein in patient sera[51], [117].  All experiments were repeated three times. 
Following initiation of treatment, cells were allowed to grow for an additional 72 
hours in the presence of TTR protein or the respective negative and positive controls.  
After the 3-day exposure interval, cell viability was assessed using the ApoToxGlo 
(Promega) assay.  Samples from 3 separate experiments were analyzed in triplicate.  The 
results (Figure 15) demonstrated that cardiac cell viability was significantly lowered in 
cells treated with the L55P and V30A samples containing oligomeric forms of TTR (t = 4 
hours); p-values were 0.0043 and 0.0159, respectively.  In contrast, treatment with V122I 
and wt TTR, as well as the BSA control, had minimal to no effect on cell viability.  It is 
interesting to note that the HMW species of BSA (Figure 14) formed after a 4-hour heat 
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treatment, unlike the TTR HMW species, were not toxic to the cells.  Staurosporine, as 
expected, induced apoptosis. 
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Figure 14.  SDS-PAGE demonstration of TTR oligomer formation in 4 hour 
denaturation assay.  
(a) TTR proteins heated to 80 °C were electrophoretically analyzed for evidence of 
tetramer dissociation and aggregation.  Aliquots of wild-type (wt), L55P, V30A, and 
V122I were removed at 0 and 4 hours of heat treatment; results are shown from left to 
right.  Wt showed minimal tetramer (T) loss and a slight increase of monomer (M), while 
L55P tetramer loss was observed by 4 hours along with the appearance of a high 
molecular weight species (H).  Both V30A and V122I showed an increased amount of 
monomer (M) by 4 hours along with the presence of dimer (D), as well as some tetramer 
(T) and HMW (H).  (b) The control protein, BSA (B), also showed the presence of HMW 
(H) aggregates in the 4-hour heat-treated sample.  Proteins were run on 10% SDS-PAGE 
gels and stained with Coomassie blue. 
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Figure 15.  Oligomers of TTR-L55P and TTR-V30A induce cytotoxicity in 
cardiomyoblasts. 
Rat cardiomyoblasts (H9C2) were exposed to staurosporine (SSP) as a positive control 
for apoptosis or TTR proteins (0.2 mg/mL) in native (untreated, 80 °C for 0 h) or 
oligomeric (80 °C for 4 h) form.  Cell viability was measured after 72 hour exposure 
using the ApotoxGlo assay (Promega).  Treatment of the cells with L55P and V30A TTR 
oligomers significantly lowered viability with p = 0.0043 and 0.0159, respectively.  Data 
were normalized to vehicle control results and are shown as averages of the triplicate 
samples from three separate experiments.  
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4.3 L55P transthyretin oligomers are internalized by rat cardiomyoblasts 
Having observed a negative effect of TTR oligomers on cell viability, we wished 
to further explore the mechanism of this cytotoxicity.  There have been numerous 
published studies suggesting that some cells have the ability to internalize certain forms 
of TTR and that specific cellular environments could promote TTR aggregation[118]–
[120].  However, these previous studies mainly focused on neuronal and other non-
cardiac cell lines.  In addition, these reports demonstrated internalization of wt TTR, 
often in its native form and there is no information regarding variant internalization.  
Fleming et al. reported on megalin-mediated native wt TTR internalization by 
neuroblastoma cells[118], and Sousa et al. observed native wt TTR internalization in 
hepatocytes[120].  An earlier study in 1990, observed native wt TTR binding to and 
internalization by hepatocytes, neuroblastoma, and lung cells[119].  Furthermore, Leung 
et al. demonstrated that L55P ATTR iPSC-derived neuronal-lineage cells internalized wt 
and L55P recombinant human TTR proteins[121].  An interesting study, published by 
Misumi et al. in 2013, described wt and V30M aggregate internalization by fibroblasts; 
however, the authors made the interesting observation that soluble native TTR protein 
was not taken up by the cells.  In addition, the aggregates reportedly were localized 
specifically to lysosomes within the fibroblasts[122]. 
To investigate whether our observation of TTR cytotoxicity was partially 
explained by internalization, cardiomyoblast cells were fixed, permeabilized, and stained 
following a 3-day exposure to the wt and L55P TTR oligomers.  We chose to test and 
compare these two TTR proteins since the strongest toxic effect was observed with the 
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L55P oligomers and little to no cell response was seen with the wt heat-treated sample.  
TTR was visualized using a FITC-tagged anti-human TTR polyclonal antibody.  DAPI 
stain was used to detect the cell nuclei and Rhodamine phalloidin allowed examination of 
F-actin filaments.  As can be seen in Figure 16, only the cells treated with TTR-L55P 
oligomers (L55P t=4 at 80 °C) displayed a striking and distinct internalization pattern of 
the protein (e), whereas cells exposed to vehicle (a), wt TTR (b,c) or native L55P (d) 
showed no immunoreactivity to the fluorescently labeled anti-TTR antibodies.  Images 
are shown at 10x magnification.  The punctuate, vesicular staining pattern seen in the 
cells treated with TTR-L55P oligomers is more apparent at a higher (40x) magnification 
as shown in Figure 17.  These results suggest that wt TTR in native and heat-denatured 
form is not taken up by cardiomyoblasts cells; alternatively, if wt TTR is internalized, the 
protein may be removed so rapidly that it does not affect cell viability.  Conversely, our 
data provides strong evidence that L55P TTR oligomers are taken up by and retained 
within the cardiomyoblasts for the 3-day duration of the experiments. 
The striking high quantities of internalized L55P TTR oligomers and distinct 
staining pattern led us to wonder whether further aggregation of TTR was occurring 
within vesicles.  A paper, published in 2009 by Hu et al., described such an observation; 
the authors reported internalization of Aβ protein by neuroblastoma cell (SH-SY5Y) 
endosomes or lysosomes and the subsequent formation of higher molecular weight 
aggregates which occurred in a time-dependent manner[123].  Based on this information, 
we stained cells after 24 or 48 hours of exposure to TTR oligomers, to more closely 
follow any changes in the aggregated state of L55P.  As shown in Figure 18, the L55P 
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TTR oligomers appeared to increase in amount and aggregate size in a time dependent 
manner. 
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Figure 16.  TTR-L55P oligomers are internalized by cardiomyoblasts. 
Rat cardiomyoblast cells (H9C2) were treated with (a) PBS vehicle, (b) native wt TTR 
(untreated, 0h at 80 °C), (c) heat-denatured wt TTR (4h at 80 °C), (d) native L55P 
(untreated, 0h at 80 °C ), or (e) oligomeric L55P TTR (4h at 80 °C).  The duration of 
treatment was 72 hours and throughout the interval, cell cultures were maintained at 37 
°C in 5% CO2.  A FITC-tagged anti-human TTR polyclonal antibody was used to detect 
TTR; DAPI stain allowed visualization of the cellular nuclei, and Rhodamine phalloidin 
was used to observe F-actin filaments.  Images were taken at 10x magnification using an 
Olympus BX60 scope.  Scale bar represents 100 µm. 
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Figure 17.  Internalized TTR-L55P oligomers display a punctate cellular pattern. 
Higher magnification (40x) of Figure 16e showing the results from rat cardiomyoblasts 
(H9C2) treated with oligomeric TTR-L55P (4 h, 80 °C) for 72 hours.  Cells were 
maintained at 37 °C in 5% CO2 for the duration of the experiment.  A FITC-tagged anti-
human TTR polyclonal antibody was used to detect TTR; DAPI stain allowed 
visualization of the cellular nuclei and Rhodamine phalloidin was used to observe F-actin 
filaments.  TTR oligomers appeared to be contained within the cytoplasm in round, 
vesicular type strictures; this result yielded a punctate staining pattern.  Images were 
taken using an Olympus BX60 scope.  Scale bar represents 100 µm. 
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Figure 18.  TTR-L55P oligomers aggregate within cells in a time-dependent manner. 
Rat cardiomyoblasts (H9C2) were exposed to (a) PBS vehicle, (b) L55P oligomers (4 h, 
80 °C) for 24 hours, or (c) L55P oligomers (4 h, 80 °C) for 48 hours.  Cell cultures were 
maintained at 37 °C in 5% CO2 throughout the duration of the experiment.  A FITC-
tagged anti-human TTR polyclonal antibody was used to detect TTR; DAPI stain allowed 
visualization of the cellular nuclei and Rhodamine phalloidin was used to observe F-actin 
filaments.  By fluorescent microscopy, we observed cellular uptake of TTR oligomers by 
24 hours; at 48 hours, internalization appeared to be continuous as an increased amount 
of TTR was visualized.  All images were taken at 10x magnification using an Olympus 
BX60 scope.  Scale bar represents 100 µm.  
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4.4 Oligomeric transthyretin induces alterations in human cardiac cell stress 
markers  
 
A collaborative effort with the laboratory of Dr. George Murphy provided the 
opportunity to enhance our cell-based studies.  Using a patient-specific disease model, we 
were able to further our testing of the effects of amyloidogenic forms of TTR on human 
cardiac cells.  Dr. Murphy and colleagues have developed a method of establishing 
patient-specific cell lines from mature somatic patient cells such as skin or peripheral 
blood[121].  Specifically, somatic cells are initially reprogrammed into pluripotent cells 
using a set of four transcription factors (Oct4, Klf4, Sox2, cMyc) that are introduced 
using retroviral vectors.  Following this step, the aforementioned factors can be excised 
resulting in induced pluripotent stem cells (iPSC) that share many characteristics with 
embryonic stem cells (ESC).  Cardiac cells can then be generated from the iPSC lines.  
The creation of cardiac cell lines from patient specimens represented an opportunity to 
further investigate the effects of amyloidogenic forms of TTR in a novel and cutting-edge 
experimental model. 
To validate our data showing the cytotoxic effects of TTR oligomers on rat 
cardiac cells and to put our studies more in the context of ATTR amyloidosis, we sought 
the use of this human cell system.  Fibroblasts obtained from an individual with L55P 
ATTR amyloidosis were reprogrammed into iPSCs and subsequently differentiated into 
cells that grow as cardiac embroid bodies (cEBs) using a seven day protocol as described 
in Chapter 2.  In addition, iPSCs derived from a healthy human subject (coded as BU6) 
were studied and served as a non-ATTR control.  Similar to the rat cardiomyoblast 
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experiments, we treated cEBs with either heat-denatured wt or oligomeric L55P; in 
addition, heat-denatured BSA served as a negative control for these studies.  After a 3-
day exposure to protein samples, the cEBs were lysed and RNA was extracted from the 
cell lysates using a Qiacube automated RNA isolation protocol.  After RNA 
quantification, cDNA was synthesized and prepared for qPCR experiments.  For our 
qPCR analysis, several stress and cell cycle markers were analyzed and included matrix 
metallopeptidase 9 (MMP9), cardiac troponin (cTnT), heme oxygenase 1 (HO1), heat 
shock protein 27 (Hsp27), and p21.  Each of these markers has been implicated in cell 
stress and/or cardiac amyloid pathology as detailed in the following paragraph.  Data was 
normalized to GAPDH expression and triplicate measurements were performed. 
MMP9, also known as gelatinase B, is an enzyme that can degrade the 
extracellular matrix (ECM) and is involved in myocardial remodeling[124], [125].  
Reactive oxygen species (ROS), as well as myocardial infarction, have been shown to 
increase MMP9 expression[126].  Troponin expression has been shown to be increased in 
the failing heart[127] and circulating troponin levels were found to be elevated in 
ATTRwt patients[56].  HO1, a stress response protein, has been shown to be induced in 
response to stress and increased expression of the enzyme is considered to be 
protective[128], [129].  Increased expression of Hsp27 has been inversely correlated with 
cell proliferation[130], shown to inhibit apoptosis during chemical stress, and reported to 
enhance degradation of ubiquitinated protein[131].  P21 expression is induced upon DNA 
damage through both p-53 dependent and independent transcription activation pathways.  
Overexpression of p21 inhibits cell proliferation and promotes cell cycle arrest[132]. 
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Treatment of the control cEBs (BU6) with native and heat-denatured forms of wt 
and L55P TTR samples yielded varying, but non-significant differences in the expression 
analyses.  It is interesting to note that MMP9 levels for all samples were higher than the 
vehicle (PBS) control; this could imply that exposure to any TTR induced a response or 
pathway that led to elevated amounts of MMP9.  In addition, cardiac troponin seemed to 
be negatively affected by the exposure to TTR-L55P regardless of oligomeric status 
(Figure 19).  Unfortunately, due to a limited number of experimental data points, we 
were not able to perform statistical analysis to determine the significance of these 
findings. 
The stress marker, HO1, did not show any significant changes in expression level 
when comparing the different treatments.  Even though HO1 levels in the PBS and wt 
TTR (80 °C for 0h) samples appeared to be lower, these were single measurements and 
therefore, we could not draw any significant conclusions.  Hsp27 expression was higher 
across all treatments compared to the vehicle control, but these were data from a single 
experiment and limit our interpretation.  Similarly, p21 showed no changes amongst 
treatments; both wild-type and L55P proteins elicited similar expression levels.  These 
data may indicate that healthy cEBs were minimally affected by the presence of native or 
amyloidogenic forms of TTR. 
In addition to studying healthy subject-derived cEBs, we repeated these 
experiments in cEBs derived from an individual with ATTRm amyloidosis, heterozygous 
for the L55P mutation.  Cells were treated with wt and L55P forms of TTR as previously; 
the effect of aggregated BSA (80 °C for 4 h) was also studied.  Expression levels were 
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normalized to GAPDH and all samples were analyzed in triplicate.  The results are shown 
in Figure 20.  As expected, both PBS and BSA treatment translated to the similar levels 
of expression across all five markers except in the case of Hsp27.  This observation may 
be attributed to the lack of multiple measurements of the BSA time point.  Even though 
multiple experiments were run and treatments were run in duplicate, low RNA yield led 
to the loss of several of the replicates.  Since BSA aggregates were considered a negative 
control, we expected these levels to be comparable to vehicle treatment. 
Cells treated with native wt TTR (80 °C for 0h) showed a slight increase in 
MMP9 expression; however, due to the data variation, as indicated by the error bars on 
the graph, the validity of this result remains undetermined and whether this increased 
expression is indeed a significant cellular response warrants further study.  Troponin, Hsp 
27, and p21 expression levels did not appear to change following cell exposure to native, 
denatured and oligomeric forms of wt and L55P proteins.  These data imply that early 
stage forms of non-native and oligomeric TTR do not induce cellular stress at a level or 
in a mechanism that can be followed with these markers.  
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Figure 19.  Stress marker expression levels in control human cardiac cells vary in 
response to transthyretin treatment. 
Expression levels of MMP9, troponin, HO1, Hsp27, and p21 in control cEBs (BU6) 
following exposure to vehicle (PBS), native wt TTR (untreated, 80 °C for 0 h), heat-
denatured TTR (80 °C for 4h), native L55P TTR (untreated, 80 °C for 0), or oligomeric 
L55P TTR (80 °C for 4h) were measured by qPCR.  Samples were run in triplicate, 
averaged, and subsequently normalized to GAPDH.  
  
76 
 
Figure 20.  Stress marker expression levels in human ATTR-L55P cardiac cells vary 
in response to transthyretin treatment. 
Expression levels of MMP9, troponin, HO1, Hsp27, and p21 in ATTR-L55P cEBs 
following exposure to vehicle (PBS), native wt TTR (untreated, 80 °C for 0 h), heat-
denatured TTR (80 °C for 4h), native L55P TTR (untreated, 80 °C for 0), or oligomeric 
L55P TTR (80 °C for 4h) were measured by qPCR.  Samples were run in triplicate, 
averaged, and subsequently normalized to GAPDH. 
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Interestingly, an increased expression of HO1 was observed for cells exposed to 
oligomeric TTR-L55P (80 °C for 4h, Figure 20).  This result was particularly striking 
since all other treatments yielded near equal or lower expression levels for the native (80 
°C for 0h) and denatured or oligomeric (80 °C for 4h) forms of TTR, respectively.  This 
increased expression could indicate an early stage of the stress response in these cells, as 
HO1 is considered an early and high sensitivity stress response marker[133], [134].  
Significance however remains to be determined as multiple measurements are needed.  
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4.5 Summary and conclusions 
The thermal denaturation of wild-type and variant TTR proteins led to formation 
of non-native and early stage oligomers which we were able to characterize by SDS-
PAGE analyses.  Oligomerization was observed with the L55P, V30A, and V122I TTR 
proteins which all showed decreased tetramer content and concomitant increases of TTR 
monomer and oligomers following 4 hours of heating at 80 °C.  The most dramatic 
results were obtained with the L55P variant which is widely held to be an extremely 
unstable variant[47].  Conversely, wild-type TTR was only slightly denatured following 
heat treatment. 
Exposure of H9C2 rat cardiomyoblasts to denatured forms of TTR led to a 
significant decrease in cell viability, especially in cells treated with oligomeric TTR-
L55P and TTR-V30A.  Interestingly, even though V30A and V122I samples from the 
heat denaturation assay appeared to contain equivalent amounts of oligomers, based on 
SDS-PAGE analyses, the V122I oligomers did not affect cell viability; this was in sharp 
contrast to the V30A results.  These observations are consistent with several previously 
reported studies (discussed in Chapter 1) which implied that variants with lower 
stabilities in biochemical and biophysical in vitro studies are featured in ATTRm 
amyloidosis with earlier ages of onset and more aggressive disease progressions.  As was 
shown in Table 1, TTR-V30A and TTR-L55P are associated with very early ages of 
onset compared to most other amyloidogenic TTR variants.  Conversely, wild-type and 
V122I demonstrate a high degree of tetrameric stability and these TTR proteins are 
linked to amyloid diseases that feature much later ages of onset, usually beyond 60 years.  
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Results from our SDS-PAGE analysis and cell viability studies were consistent with the 
proposed correlation between TTR tetramer stability and disease phenotype. 
We expanded our cellular studies to explore internalization of TTR oligomers as a 
cause of cytotoxicity.  Indeed, we observed high levels of oligomeric L55P 
internalization.  Interestingly, this cellular uptake of TTR seemed to be time-dependent; 
TTR aggregation appeared to be further propagated once the protein was within the cell, 
a process that was monitored over the course of 48 hours.  This could also explain why 
even after 48 hours, some cells contained more aggregates compared to others; in a 
subset of cells, a more efficient seeding and aggregate growth process may have 
occurred.  We also observed a distinct granular and vesicular staining pattern of 
internalized L55P oligomers when viewed at higher magnification (40x).  A particularly 
striking observation was the apparent expansion of L55P aggregates from initial, 
localized, smaller inclusions within the cell cytosol to large globules present throughout a 
majority of the cytoplasm.  This progressive infiltration was so extensive that entire cells 
appeared to be saturated with oligomeric TTR. 
Based on the results in our rat cardiomyoblast model, we concluded that only the 
L55P oligomers, due to their extreme amyloidogenic nature, were recognized and 
internalized by cells.  Once internalized, the oligomers further associated to form 
aggregates of increasing size, either within an endosome or lysosome.  Moreover, this 
process was continuous and ultimately yielded a high concentration of aggregates that 
were cytotoxic, led to cell death, and resulted in the lowered cell viabilities observed in 
our studies. 
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In the studies of healthy subject-derived cardiac embroid bodies (BU6) treated 
with TTR oligomers, we observed little to no change in the expression levels of several 
stress and cell cycle markers.  Some fluctuations in MMP9 expression were noted in cells 
treated with denatured forms of TTR when compared to the PBS vehicle control.  
Furthermore, cardiac troponin expression appeared to be lower in cells treated with both 
native and oligomeric TTR-L55P.  Alternatively, in studies of the patient-derived ATTR-
L55P cardiac embroid bodies, treatment with oligomeric L55P led to a striking increase 
in HO1, indicating that a stress response had been triggered in these cells. 
The gene expression level data were less dramatic and striking compared to the 
cell viability results obtained in the studies of rat cardiomyoblasts.  This could be 
partially attributed to the fact that cEBs are a more robust cell type, and are grown as very 
dense three-dimensional cultures.  The 3-dimenstional nature of this cell culture system 
(versus the monolayer grown cardiomyoblasts) may impede uptake of L55P TTR 
oligomers, i.e. make it difficult for TTR oligomers to penetrate the cellular masses.  Thus, 
we would expect that a cytotoxic effect would be attenuated.  In contrast, a monolayer of 
rat cardiomyoblasts should be much more susceptible to the cytotoxic effects of TTR 
proteins; hence, one would predict that a stronger response would be elicited from cells 
that are more accessible and vulnerable to treatment. 
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CHAPTER 5.  POTENTIAL INHIBITORS OF TRANSTHYRETIN 
CARDIOTOXICITY 
5.1 Introduction  
Having demonstrated that some variant TTR oligomers cause a cytotoxic response 
in cardiac cells, we wished to study several chemical and biological agents as inhibitors 
of this negative effect.  We chose to focus on three small molecule drugs, diflunisal 
doxycycline, and Kiacta®; in addition, we investigated the ability of retinol-binding 
protein (RBP), a natural binding partner of TTR, to block TTR cardiotoxicity. 
Diflunisal was studied based on previously published in vitro work demonstrating 
the ability of the drug to stabilize native (tetrameric) TTR through binding in the T4 
attachment sites[75], [135] and encouraging results from a recent clinical trial[28].  As 
previously described (Chapter 1), the antibiotic doxycycline has been shown to disrupt 
TTR fibrils in both FAP and AL mouse models[80], [84], [87].  To our knowledge, 
doxycycline has never been studied in TTR aggregation models and has only been 
considered as a fibril disruptor.  We chose to study the effect of this drug on early protein 
aggregation, encouraged by one previous report that suggested a potential role for 
doxycycline as an inhibitor of aB crystallin aggregation[80].  Moreover, concurrent with 
the cellular studies detailed in Chapter 4 and in parallel with biophysical analyses 
performed in our laboratory, the opportunity to explore the inhibitory potential of a novel 
compound, Kiacta®, arose through an ongoing collaboration with the pharmaceutical 
company, Neurochem Inc.  Kiacta® had formerly been shown to inhibit fibril 
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polymerization and amyloid deposition[81].  The effects of the compound on TTR 
aggregation and cytotoxicity were unknown. 
Our investigations also included studies aimed at exploring the role of RBP, a 
natural binding partner of circulating TTR, in ATTR amyloidosis.  As mentioned 
(Chapter 1), RBP4 is the only secreted RBP isoform and normally is present in the 
bloodstream complexed to TTR; the binding of RBP4 to TTR stabilizes the native form 
(tetramer) of the latter protein and prevents disassembly into monomers[96], [97].  These 
data suggest that the biological role of RBP4 directly affects TTR amyloidogenicity; 
indeed, RPB4 may act as an anti-amyloid agent.  A perturbation of the RBP4-TTR 
association might offer a partial explanation of why ATTR disease usually features 
delayed onset of symptoms.  Thus, we sought to characterize RBP4 in ATTR amyloidosis 
to further define the mechanism of disease.  
5.2 Doxycycline inhibits transthyretin-induced cytotoxicity 
The ability of doxycycline to block the toxic effect of oligomeric TTR on cardiac 
cells was tested.  Briefly, TTR proteins (0.4 mg/mL) were thermally denatured for 4 
hours at 80 °C in the presence of 50x molar excess doxycycline.  As before, we included 
untreated (0 hour, no heat treatment) and 4-hour heat-treated TTR samples for 
comparison.  Sample solutions were mixed 1:1 with complete medium and applied to the 
rat cardiomyoblast (H9C2) cultures; the cells were treated for 72 hours and then assessed 
for cell viability.  Viability was measured using the ApotoxGlo assay (Promega) and data 
were normalized to vehicle control.  Samples were tested in triplicate and each 
experiment was repeated three times.  Data from all experiments were averaged and 
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significance calculated by two-tailed Student’s t-test and Mann-Whitney post-test.  A p-
value < 0.05 was considered significant.  
The results of these experiments are represented by histograms and shown in 
Figure 21.  Cells treated with TTR-L55P or TTR-V30A thermally denatured in the 
presence of doxycycline (80 °C for 4 h + Dox), showed a significant improvement in cell 
viability compared to cells exposed to oligomers formed in the absence of drug (80 °C for 
4 h).  P-values were equal to 0.0357 for both comparisons (TTR-L55P or TTR-V30A vs. 
TTR-L55P or TTR-V30A + Dox).  While the damaging consequence of oligomeric L55P 
on cells appeared to be lessened by doxycycline, the presence of drug did not totally 
abolish the effect (90% of control).  However, while TTR-V30A oligomers decreased cell 
viability, the presence of doxycycline abrogated this effect as demonstrated by cell 
viability (80 °C for 4 h + Dox) nearly equal to the control group (80 °C for 0 h).  In 
contrast, doxycycline showed no effect in the cells treated with the wt or V122I TTR 
proteins. 
These results suggested that the presence of doxycycline in TTR solutions during 
the thermal denaturation process either partially prevented or slowed the formation of 
toxic oligomers species.  Alternatively, doxycycline may have induced the degradation, 
disassembly, or restructuring of the oligomeric species thus, rendering them no longer 
toxic to cells.  The ability of doxycycline to block cytotoxicity appeared to be TTR 
variant specific, as little to no effect was observed in cells treated with either the wt or 
V122I TTR samples.  
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Figure 21.  Doxycycline abrogates the cytotoxic effect of some transthyretin 
variants. 
Rat cardiomyoblast (H9C2) cells were treated with staurosporine (SSP), native TTR (80 
°C for 0 h), or oligomers (80 °C for 4 h); final TTR concentrations were 0.2 mg/mL.  
Viability measurements of cells after 72 hours of treatment were performed using the 
ApotoxGlo (Promega) assay.  Compared to the oligomer-treated cells (80 °C for 4 h), 
cells exposed to TTR-L55P or TTR-V30A samples with 50x molar excess doxycycline 
(80 °C for 4 h + Dox) showed significantly increased cell viability (p = 0.0357 for both 
comparisons).  Results were normalized to vehicle control and are shown as averages of 
triplicate samples in three experiments.  Significance was calculated by two-tailed 
Student’s t-test and Mann-Whitney post-test; p-value < 0.05 was considered significant. 
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5.3 Doxycycline partially inhibits formation of transthyretin oligomers 
It was important to biochemically characterize the effect of doxycycline on the 
thermal denaturation of TTR.  In parallel with the cell-based studies, we analyzed the 
oligomeric forms of TTR generated by heat treatment in the presence of doxycycline 
using chemical cross-linking and electrophoretic analysis.  Briefly, TTR samples, with 
and without drug, were heated (80 °C) for 4 hours, cross-linked with glutaraldehyde, and 
analyzed by SDS-PAGE.  As in other experiments, BSA was similarly treated and served 
as a control.  The SDS-PAGE results for TTR and BSA are shown in Figure 22. 
The presence of doxycycline during heat treatment of wild-type TTR (Figure 
22a) did not prevent the loss of tetrameric TTR (T).  Moreover, the unanticipated 
appearance of a high molecular weight (H) protein band (not observed in the adjacent 
lane containing thermally denatured TTR, no doxycycline) indicated that tetrameric TTR 
was less stable in solution with drug.  One possible explanation for this finding may be 
inappropriate storage of the protein test solution; the wt TTR sample, to which 
doxycycline was added, had been stored at 4 °C for 4 hours.  Sörgjerd et al. have shown 
that storage of TTR at 4 °C leads to aggregation of the protein[20].  Of note, these 
aggregated species of wt TTR, only faintly visible on the SDS-PAGE gel, were likely low 
in abundance or not cytotoxic as there was no detectable effect of this TTR on cell 
viability (Figure 21).  In contrast, L55P oligomer formation was drastically reduced in 
the presence of doxycycline even though the drug did not prevent the loss of L55P TTR 
tetramer (T); the absence of tetramer and appearance of monomer (M) and dimer (D) 
suggested that native TTR had undergone nearly complete dissociation.  The effect of 
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doxycycline in heated samples of V30A was loss of TTR tetramer (T) and dimer (D) 
content in the absence of high molecular weight aggregate (H) formation.  TTR-V122I 
showed a decreased amount of high molecular weight oligomers (H) in the presence of 
doxycycline, as well as a loss of tetramer (T) and dimer (D); a slight increase in 
monomeric species (M) was also observed.  Interestingly, the presence of doxycycline 
also seemed to prevent the aggregation of non-amyloidogenic BSA protein (Figure 22b). 
Taken together, these data suggest that doxycycline does not bind to and stabilize 
tetrameric TTR, as monomers and/or dimers from dissociation of the intact protein were 
clearly visible.  One inference from the results is that the drug interacts with non-native 
TTR intermediate conformations formed in the transition between monomer and high 
molecular weight species.  Doxycycline appeared to promote tetrameric dissociation 
while preventing formation of the high molecular weight soluble oligomers possibly by 
stabilizing the monomers and interfering in self-association of the subunits. 
Our hypothesis that doxycycline does not interact or bind to tetrameric TTR, but 
instead acts on the smaller monomeric and dimeric species, was supported by circular 
dichroism analyses (Figure 23).  Using wild-type and L55P, mixtures of each TTR with 
doxycycline were analyzed for structural changes in the far UV range (195 – 250 nm).  
The spectral signal of each mixture was compared to a computed signal obtained by 
summing the separate CD signals of TTR protein and doxycycline.  The mixture and 
calculated spectra for wt TTR and doxycycline were superimposable; a near perfect 
overlap of signals was also seen for L55P and doxycycline.  These data provided strong 
evidence that no secondary structural changes in TTR occurred when drug was present; 
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these results imply that there was no interaction between tetrameric TTR and 
doxycycline. 
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Figure 22.  The presence of doxycycline during thermal denaturation of 
transthyretin partially prevents formation of high molecular weight oligomers.  
The characterization of TTR dissociation following 4 hours at 80 °C in the presence or 
absence of 50x molar excess doxycycline (Dox) was accomplished using SDS-PAGE.  
From left to right, wt TTR showed tetramer (T) loss and a slight increase in oligomers 
(H) in the presence of drug.  L55P showed complete abolishment of high molecular 
weight species (H).  Both V30A and V122I showed a decrease in dimer (D) and tetramer 
(T) content.  (b) BSA in native (B) and high molecular weight (H) forms are shown 
before (0) and after (4) heating; heating in the presence of doxycycline resulted in a 
diminished amount of large aggregates (H).  Protein samples were run on 10% SDS-
PAGE gels and stained with Coomassie blue. 
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Figure 23.  Doxycycline and tetrameric transthyretin do not interact as evidenced by 
circular dichroism spectroscopy. 
Far-UV spectra were generated for mixtures of doxycycline and TTR, wild-type TTR 
(top panel), and TTR-L55P (bottom panel); monitoring was performed at room 
temperature between 195 and 250 nm.  TTR solutions were 0.2 mg/mL in PBS and 
contained 50x molar excess of doxycycline.  Additive signals (blue) were computed by 
summing the individual TTR and doxycycline CD signals.  The near indistinguishable 
overlap in the additive and mixture curves for both wt and L55P demonstrates little to no 
interaction between doxycycline and native (tetrameric) TTR.  
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5.4 Internalization of transthyretin oligomers is inhibited by doxycycline 
In order to further understand how doxycycline lessened the cytotoxic effect of 
oligomeric TTR, we extended our internalizations studies to include samples with and 
without drug.  Briefly, rat cardiomyoblast (H9C2) cells were treated with TTR protein 
(0.2 mg/mL) that had been thermally denatured in the presence (50x molar excess) or 
absence of doxycycline.  Following a 3-day exposure, the cells were fixed, 
permeabilized, and stained for TTR oligomers, nuclei, and F-actin filaments using FITC-
tagged anti-human TTR antibody, DAPI stain, and rhodamine phalloidin, respectively.  
As shown in Figure 24a, vehicle treated cardiomyoblasts appeared healthy with abundant 
F-actin filaments (red) and well-defined nuclei (blue); no TTR (green) was observed.  As 
in prior experiments, cells treated with L55P oligomers showed heavy staining for TTR 
within the cells (Figure 24b); this result indicated that cellular uptake of TTR oligomers 
had occurred.  Retention of TTR oligomers within the cells appeared to be in vesicular 
type structures or organelles.  In stark contrast, the cells that were exposed to the 
thermally denatured preparations of L55P and doxycycline (Figure 24c) showed little to 
no TTR oligomers within the cells. 
These results with drug were consistent with our previous studies showing that the 
presence of doxycycline drastically reduced the formation of L55P oligomers by thermal 
denaturation.  It seems reasonable to assume that TTR internalization was not detected 
due to the scarcity of oligomers in the treatment sample as a consequence of doxycycline.  
In addition, this effect of doxycycline translated to an improvement in cell viability when 
present with TTR.  Taken together, the cell viability, electrophoretic, circular dichroism, 
  
91 
and fluorescence microscopy data suggest that 1) doxycycline inhibits the formation of 
high molecular weight oligomers of TTR-L55P possibly through stabilizing interactions 
with the monomers, and 2) protects cells from the cytotoxic effect of TTR aggregates 
which may be mediated through aggregate internalization.  
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Figure 24.  Presence of doxycycline during thermal denaturation significantly 
reduces internalization of TTR-L55P oligomers.  
Rat cardiomyoblasts (H9C2) were treated with (a) vehicle, (b) L55P previously heated 
for 4 h at 80 °C, or (c) L55P + doxycycline previously heated for 4 h at 80 °C; the 
duration of treatment was 72 hours during which cells were incubated at 37 °C in 5% 
CO2.  TTR oligomers (green) appear to be contained within the cytoplasm in round, 
vesicular type structures which yields a punctate staining pattern.  Results for TTR 
(green), nuclei (blue), and F-actin (red) are shown.  Images were taken at 40x 
magnification using an Olympus BX60 scope.  Scale bar represents 100 µm.  
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5.5 Kiacta® and diflunisal do not inhibit transthyretin-related cytotoxicity 
As with the studies of doxycycline, we sought to determine whether Kiacta® and 
diflunisal could block the cardiotoxic effects of oligomeric TTR.  Briefly, rat 
cardiomyoblast cells were seeded in 96-well plates and exposed to wt or L55P TTR 
proteins (0.2 mg/mL), that had been previously heated (80 °C) for 0 or 4 hours in the 
presence (10x or 100x molar excess) or absence of drug.  Results obtained from the cell 
viability experiments, shown in Figure 25, demonstrated that Kiacta® had no effect on 
cells treated with the wt or L55P TTR samples.  In addition, it appeared that the presence 
of diflunisal in the L55P oligomer samples (80 °C for 4 h + diflunisal 1:10 or l:100) 
actually had a slightly adverse effect on cell viability.  The diflunisal data are most likely 
a consequence of structural changes in the drug induced by the 80 °C heat treatment; 
indeed, we found published thermal analysis data demonstrating that decarboxylation of 
diflunisal occurs upon heating[136]. 
It is important to note that neither heat-denatured wt nor L55P TTR (80 °C for 4 
h) elicited a change in the viability of the cardiac cells.  This did not appear to be a 
technical problem with the assay as the cells treated with staurosporine (SSP), a positive 
control for apoptosis, showed a dramatic decrease in cell viability, i.e. a reduction in 
viability of almost 90%.  Furthermore, the absence of decreased cell viability in cells 
treated with L55P oligomers (80 °C for 4 h), as had been observed in repeated earlier 
experiments, was unexpected.  This result may have been due to the use of cells that were 
passaged a greater number of times and over a longer period of time, compared to cells 
used in the previous experiments.  We concluded that this cell line, H9C2, undergoes 
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alterations as passage number increases, i.e. the cells become more desensitized over 
time.  Our conclusion is strengthened by other studies with H9C2 cells that use 
consistently low passage numbers in cell death and apoptosis experiments[137], [138]. 
Biochemical analyses of the wt and L55P samples, heat-denatured in the presence 
or absence of Kiacta®, were performed using SDS-PAGE (Figure 26).  With wild-type 
TTR, no differences were observed in the samples with and without drug.  Interestingly, 
we did observe an effect of Kiacta® in the L55P TTR oligomer (H) sample.  TTR-L55P, 
heated for 4 h in the absence of Kiacta®, contained high molecular weight oligomeric 
species (H), as previously demonstrated.  However, when TTR-L55P was thermally 
denatured in the presence of 50x molar excess of Kiacta ®, little to no high molecular 
weight species were apparent on the SDS-PAGE gel.  These observations imply that 
Kiacta® may, in fact, inhibit the formation of TTR-L55P oligomers.   
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Figure 25.  Effect of Kiacta® and diflunisal on the transthyretin-induced cytotoxic 
response of cardiac cells.  
Rat cardiomyoblast cells were treated with 0.2 mg/mL TTR (wild-type or L55P), that had 
been previously incubated for 0 or 4 hours at 80 °C in the presence or absence of Kiacta® 
or diflunisal (1:10 or 1:100 molar ratio of protein to drug).  No changes in viability were 
noted in cells treated with the heated (80 °C for 4 h) wild-type TTR alone or in the 
presence of either concentration of Kiacta ®; the results for L55P were similar.  For cells 
treated with samples containing diflunisal, a decrease in cell viability was observed; 
however, this result was most likely due to heat-induced structural changes in diflunisal 
which likely altered the properties of the drug.  Cell viability is shown as % of control 
(PBS).  Staurosporine (SSP) served as a positive control for apoptosis.  
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Figure 26.  Kiacta® inhibits transthyretin oligomer formation. 
Wild-type and L55P TTR protein samples were heated for 4 hours at 80 ⁰C in the 
presence or absence of Kiacta® at 50x molar excess.  Samples were cross-linked with 
25% glutaraldehyde and analyzed by SDS-PAGE (10%).  In the wild-type samples with 
and without Kiacta®, no significant differences were noted; tetrameric (T) TTR was most 
abundant with little evidence of the high molecular weight (H) form.  Analysis of the 
TTR-L55P samples with and without drug suggested that the presence of Kiacta® 
inhibited formation of TTR oligomers as a decrease in the high molecular weight (H) 
species was observed.  
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5.6 Retinol-binding protein slows the rate of transthyretin aggregation  
Retinol-binding protein (RBP) is a natural partner of TTR and normally circulates 
as a ternary complex of TTR-RBP-vitamin A[89].  Previous studies have shown that 
RBP, in the absence of vitamin A and referred to as apoRBP, reportedly has a lowered 
affinity for TTR compared to holoRBP, i.e. RPB complexed to retinol[139].  This may, in 
part, be due to conformational changes that occur in RBP upon binding to vitamin A 
making the protein structure of RBP more favorable for interactions with tetrameric TTR.  
Raghu et al. have reported a much higher binding affinity of holoRBP for native TTR 
compared to apoRBP (8x10
-6
 (Kd) M
-1
 vs. < 8x10
-6
 (Kd) M
-1
 to no binding)[29].  This 
information, along with data showing that RBP stabilizes the tetrameric form of TTR[97], 
prompted us to investigate the effect of  RBP on in vitro TTR aggregation.  We 
hypothesized that holoRBP would inhibit formation of oligomeric TTR. 
To test our theory, we analyzed solutions of TTR with and without holoRBP; 
holoRBP was prepared immediately prior to these experiments by incubation of the 
protein in an excess of vitamin A (all-trans retinol).  Protein solutions of TTR-L55P, 
holoRBP, and TTR-L55P + holoRBP were prepared in PBS and heated to 80 °C for 1 
hour.  The mixture containing TTR-L55P and holoRBP was prepared with a 1:1 molar 
ratio of the two proteins to represent the physiologic situation.  TTR-L55P was chosen 
for these experiments because it is a highly unstable variant.  Whereas wild-type TTR has 
a melting temperature > 98 °C, L55P will begin to unfold at 65 °C.  Thus, we felt that 
TTR-L55P would be easily and more rapidly destabilized, and most appropriate for our in 
vitro studies.  To assess progression of TTR aggregation, we monitored protein 
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absorbance changes in aliquots removed at 10 minute intervals from each sample, over 
the course of 60 minutes (1 hour).  Absorbance was measured at two wavelengths, 280 
and 340 nm.  For each sample, the aggregation rate was represented as an aggregation 
index (AI) and calculated with the following formula:  
AI = 100 x (A340nm / (A280nm -A340nm)) 
where A340nm and A280nm are absorbance values recorded at 340 and 280 nm, respectively.  
The results of this experiment are shown in Figure 27.  The data demonstrate that the 
TTR-L55P (black) had the quickest rate of aggregation, as was expected; by 20 minutes, 
the AI was approximately equal to 3 and increased to 4 by 60 minutes.  For holoRBP 
(red), rapid aggregation was also observed with an AI of about 2 by 20 minutes and 3.5 
by 60 minutes.  This was an anticipated result as holoRBP is a small protein which is 
denatured at 80 °C.  In contrast, the aggregation rate for the 1:1 mixture of TTR + 
holoRBP (blue) was significantly lower than either protein alone, with AI = 1.5 at 20 
minutes and AI = 2 by 60 minutes. 
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Figure 27.  Stabilization of transthyretin by retinol-binding protein during thermal 
denaturation.  
Solutions of TTR, holoRBP, and TTR + holoRBP (1:1 molar ratio) were heated for 60 
minutes at 80 ºC to induce protein aggregation.  Protein absorbance measurements were 
recorded on aliquots removed at approximately 10 minute intervals from each sample.  
The rate of aggregation was expressed as an aggregation index (AI), calculated from 
absorbance measurements recorded at wavelengths of 280 and 340 nm.  TTR (black) 
showed the quickest rate of aggregation, AI = 3 at 20 min and AI = 4 at 60 min; holoRBP 
(red) also demonstrated aggregate formation, but at slower rate than TTR (AI = 2 at 20 
min and AI = 3.5 at 60 min).  In contrast, the aggregation rate in the 1:1 (molar ratio) 
mixture of TTR:holoRBP (blue) was significantly lower with AI =1.5 at 20 min and AI = 
2 at 60 min. 
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5.7 Retinol-binding protein is not complexed to transthyretin in cardiac amyloid 
deposits 
Our in vitro data provided evidence that RBP slowed the aggregation of 
thermally-denatured TTR; this finding implied that RBP was stabilizing native TTR.  
Therefore, we hypothesized that TTR found in amyloid deposits would no longer be 
bound to its natural and stabilizing binding partner, holoRBP.  To investigate our theory, 
we performed immunohistochemical staining for RBP and TTR in autopsied heart 
samples heavily infiltrated with TTR amyloid.  Formalin-fixed, paraffin-embedded 
cardiac tissues were sectioned and used in these analyses; the presence of amyloid 
deposits in all tissue sections was confirmed by Congo red staining and resultant green 
birefringence by polarized light microscopy. 
Specifically, we used serial sections of autopsied heart tissue from a patient who 
had been diagnosed with ATTR-L58H amyloidosis (Figure 28).  In a Congo red treated 
section, heavily stained areas of tissue were observed by standard light microscopy 
(Figure 28a); a polarized view of the same field (Figure 28b) exhibited ‘apple green’ 
birefringence thus, confirming the presence of amyloid in the section.  Immunohisto-
chemical staining of a serial section with anti-human TTR antibodies (Figure 28c) 
demonstrated that TTR was the amyloid protein constituent of the deposits.  For our RBP 
analyses, we tested several anti-human RBP antibodies.  Initial attempts at 
immunohistochemical staining rendered results that suggested non-specific antibody 
binding to the tissue.  One antibody preparation, appeared to recognize the cellular 
isoform (RBP1, also known as CRBP) and not the serum isoform (RBP4) which we were 
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investigating (Figure 28d).  Of note, the cellular form has been shown to be strongly up-
regulated during myocardial stress[140].  Subsequent testing was performed with an 
RBP4-specific antibody (Abcam, ab48624); the immunohistochemical results with this 
antibody showed minimal cellular staining (little background) and there was no evidence 
of RBP in TTR amyloid deposits (Figure 28e).  Thus, our immunohistochemical staining 
using antibodies against RBP4 and TTR demonstrated that TTR was present in the 
amyloid deposits, whereas RBP4 was absent. This finding indicated that the two proteins 
were no longer associated and implies that the formation of TTR amyloid may, in part, be 
due to a decrease in the stabilizing effect of RBP on native (tetrameric) TTR. 
5.8 Serum retinol-binding protein is present in amyloid-infiltrated heart tissue  
Using an antibody that specifically recognized serum RBP4 and did not react with 
other cellular isoforms of the protein, we extended our immunohistochemical analyses to 
include heart tissue sections from cases of ATTRwt and AL amyloidosis.  Liver tissue 
sections from a patient with AL amyloidosis were used as positive controls since the liver 
is the main production site of RBP4; transplanted heart tissue sections from a patient with 
ATTR-T60A amyloidosis who had undergone cardiac transplantation and received a 
‘non-amyloid’ heart eight years prior to death were used as a ‘non-amyloid’ control.  As 
expected, our positive control (liver tissue) stained strongly for RBP4 (Figure 29a) and 
could be easily observed at 10x magnification.  Although our negative control (Figure 
29b), a section not treated with primary antibody, appeared negative to the naked eye, we 
did observe a faint background staining which was granular in appearance at 40x 
magnification (Figure 29d).  The brown stained material was identified as lipofuscin 
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(with expert input from Dr. Carl O’Hara), a cellular waste resulting from oxidative 
reactions that accumulates within the lysosomes; the presence of lipofuscin is considered 
a hallmark of aging[141], [142].  Lipofuscin staining was observed in ATTRm (Figure 
29f, i) and AL heart tissue sections (Figure 29h, k).  Interestingly, RBP4 staining was 
noted in the transplanted ‘non-amyloid’ heart (Figure 29c); at 40x magnification (Figure 
29e), this staining for RBP4, not due to lipofuscin, appeared to be located in the 
cytoplasm of the myocytes.  Particularly intriguing was the appearance of localized areas 
of staining, in regions of slight collagen infiltration and early signs of ischemia.  
In addition to the transplant heart, wild-type ATTR patient tissue also stained 
strongly for RBP4 around amyloid infiltrated vasculature (Figure 29 g, j).  Further 
histologic analysis of the ATTRwt heart tissue was performed (Figure 30a).  Amyloid 
deposition in the vasculature was confirmed by Congo red staining in near serial sections 
of the tissue (Figure 30b, c).  Of note, all sections shown in Figure 30 were from the 
same tissue block; however, the section used for RBP4 immunohistochemical testing 
(Figure 30a) was an earlier cut in the series, whereas Congo red staining (Figure 30b) 
was performed on a section cut approximately 50 um later.  The tissue architecture in 
these sections was not identical; however, based on the location within the tissue, it 
seemed likely that we were viewing the same blood vessel in the center of the image.  As 
with the transplanted heart tissue section, the ATTRwt tissue appeared to exhibit early 
hallmarks of ischemia characterized by wavy fibers and variation in cell size and shape.  
Our results suggest that these two hearts, possibly infiltrated by early-stage wild-type 
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TTR amyloid, appear to have RBP4 present in tissue directly surrounding the infiltrated 
area.  
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Figure 28.  Histological and immunohistochemical analyses of ATTR-L58H heart 
tissue. 
Serial sections of autopsied heart tissue from a patient with ATTR-L58H were stained 
with Congo red and viewed by (a) standard and (b) polarized light microscopy.  Proof of 
amyloid was demonstrated by the appearance of (a) salmon-colored deposits that 
exhibited (b) green birefringence on polarization.  Immunohistochemical staining with (c) 
anti-human TTR antibody confirmed the presence of TTR in the amyloid deposits, 
whereas (d) anti-human RBP1 antibody treatment showed strong reaction with 
intracellular protein, and (e) anti-human RBP4 antibody staining was negative in the 
deposits indicating that there was no co-localization of RBP with TTR amyloid.  All 
images are at 10x magnification.  Scale bar represents 100 µm. 
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Figure 29.  Immunohistochemical testing for serum retinol-binding protein in 
control and amyloid tissues. 
Tissue sections of autopsied liver and heart tissues were analyzed for the presence of 
RBP4 by immunohistochemical staining.  Shown are a (a) positive control – liver tissue, 
the site of RBP4 production, (b) negative control – heart tissue not treated with primary 
RBP4 antibody that showed faint granular staining identified as lipofuscin, (c) 
transplanted heart tissue exhibiting strong staining for RBP4 located in an area with 
collagen infiltration, (d) negative control boxed area in panel (b) at 40x magnification, (e) 
transplanted heart tissue boxed area in panel (c) at 40x magnification, (f) ATTRm heart 
staining negative, (g) ATTRwt heart staining positive around vessel, and (h) AL heart 
staining negative.  Unless otherwise indicated, images are shown at 10x magnification.  
Scale bars represent 100 µm.  
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Figure 30.  Histological and immunohistochemical analyses of ATTRwt heart tissue. 
Near serial sections of autopsied heart tissue from a patient with ATTRwt amyloidosis 
were stained with Congo red and compared to the previous RBP4 immunohistochemical 
testing results.  (a) Immunohistochemical analysis (from Figure 29j) for RBP4 indicated 
the presence of the protein in areas proximal to a blood vessel.  (b) Congo red staining 
showed strong areas of dye binding around the myocytes and blood vessel by standard 
light microscopy and (c) green birefringence by polarized view.  Images are 10x 
magnification.  
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5.9 Serum retinol-binding protein concentrations are varied in ATTR amyloidosis 
Based on our immunohistochemical evidence that TTR protein in ATTRm 
amyloid deposits was not bound to RBP4, we theorized that RBP4 levels in ATTR sera 
would be decreased and correlated to increased amounts of unbound TTR.  Abnormally 
low serum levels of RBP4 in patients with TTR-associated amyloidosis could potentially 
explain increased native TTR destabilization leading to the formation of TTR amyloid 
fibrils. 
With samples from the Amyloidosis Center serum repository obtained under 
protocols (IRB# H-22838 and H-28609) approved by the Boston University School of 
Medicine Institutional Review Board, we developed an ELISA to measure serum RBP4 
concentrations in several patient and control groups.  Plate to plate reproducibility was 
confirmed and inter-and intra-plate variability values (CV) were below 10.  The goal was 
to assess and compare the serum levels of RBP4 in the following age-matched groups:  1) 
healthy controls, 2) ATTRwt (wild-type TTR-associated) amyloidosis, 3) ATTRm 
(mutant TTR-associated) amyloidosis featuring cardiomyopathy (CMP), 4) AL 
(immunoglobulin light chain-associated) amyloidosis with CMP, and 5) non-amyloid 
with CMP (sera kindly gifted by Dr. Flora Sam).  The results of the ELISA 
measurements are shown in Figure 31.  RBP4 levels were significantly higher in the 
ATTRwt (47,000 vs. 38,000 ng/mL, p = 0.03) and AL groups (50,000 vs. 38,000 ng/mL, 
p = 0.04) when compared to controls.  In contrast, RBP4 was significantly lower in 
ATTRm with CMP (30,000 vs. 38,000 ng/mL, p = 0.02) compared to controls.  Serum 
RPB levels were significantly different in ATTRm and AL (50,000 vs.30,000 ng/mL, p = 
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0.005), as well as in ATTRwt and ATTRm (47,000 vs. 30,000 ng/mL p > 0.0001).  The 
CMP non-amyloid serum samples showed increased RBP4 serum levels compared to 
controls (41,000 vs. 38,000 ng/mL); however, due to low number of samples and large 
amount of error this difference was not deemed significant.  
These data demonstrated varied concentrations of RBP4 among the amyloid 
groups, all significantly different compared to controls.  It was particularly intriguing to 
us that the TTR-associated amyloidosis groups, ATTRwt and ATTRm, showed opposite 
trends in serum RBP4 levels.  These results prompted us to ask whether these changes in 
RBP4 serum levels were reflected or correlated in any way to circulating TTR levels.  
Our aim was to measure TTR concentrations in the same sets of sera and the 
development of a TTR ELISA was undertaken.   
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Figure 31.  Levels of retinol-binding protein in control and amyloid patient sera 
measured by ELISA. 
Using an ELISA developed as part of this thesis research, RBP4 levels (ng/mL) were 
measured in serum samples from several age-matched groups:  healthy controls, ATTRwt 
(wild-type TTR-associated) amyloidosis, ATTRm (mutant TTR-associated) amyloidosis 
featuring cardiomyopathy, AL (immunoglobulin light chain-associated) amyloidosis with 
cardiomyopathy, and non-amyloid with cardiomyopathy (CMP no amyloid) sera kindly 
provided by Dr. Flora Sam.  Compared to the control group, RBP4 was significantly 
higher in ATTRwt (p = 0.03) and AL (p = 0.04), but significantly lower in ATTRm (p = 
0.02).  In addition, RBP4 levels were significantly different between ATTRwt and 
ATTRm (p < 0.0001), as well as ATTRm and AL (p = 0.005).  Sera were measured in 
triplicate; n represents the number of sera tested in each group.  
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5.10 Transthyretin enzyme-linked immunosorbent assay development 
To further understand the RBP4 data in the context of TTR amyloid diseases, we 
sought to measure circulating TTR levels in patient sera.  Initially, two commercial kits 
(Abcam) were used in a pilot study of a small collection of samples; however, the inter-
plate variability was incredibly high (CV > 20) and inconsistent (non-reproducible) inter-
assay results were obtained for some, but not all, serum samples.  Concentration values 
did appear to be within the accepted limits for serum TTR, 200 – 450 µg/mL for normal, 
< 200 µg/mL for ATTR[27], [51], and data from the commercial ELISA kit (Figure 32) 
showed a striking difference between the control and ATTRm sera (190,000 vs. 350,000 
ng/mL, p = 0.04).  However, the group numbers were low and are a limitation in this 
analysis.  Concerned with the reliability of these data, we investigated other 
commercially available TTR ELISA kits and found that all required extremely high 
dilutions of serum (1:100,000); this would require numerous dilution steps and increase 
the probability of variability and no doubt increase chance of error.  Thus, we attempted 
to establish an ELISA in our laboratory that would be accurate and reproducible in 
measurements of serum TTR concentrations. 
The initial step in development of the TTR ELISA was validation of coating and 
detection antibody dilutions; optimal antibody concentrations for coating and detection 
were 1:500 and 1:8,000, respectively.  Absorbances were measured at 465 and 570 nm.  
Moreover, we found casein to be the most efficient blocker, minimizing background 
signal to near-zero values.  TTR, purified from pooled sera (Sigma) was used for standard 
curve construction; signal to noise ratios were > 100.  A representative standard curve for 
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the TTR ELISA is shown in Figure 33.  The data display the optimal characteristics for a 
standard curve; it is typical in sigmoidal shape with low background and allows for a 
sizeable distribution of concentration measurements, spanning an appropriate linear 
concentration range of 10-100 ng/mL between 0.5 and 3.0 absorbances.  Surprisingly, the 
initial ELISA testing of patient sera yielded little to no TTR signal in any of the samples; 
low absorbance values indicated that TTR in the serum samples was not being captured 
and/or detected by the antibodies.  Concentrations of the standard solutions containing 
purified TTR, however, were always accurately and reproducibly generated.  We 
concluded that TTR, in a complex milieu like serum, is less available for immune 
complex formation possibly due to epitope masking or crowding effects that prevent 
antibody recognition.  
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Figure 32.  Serum transthyretin levels in control and ATTR sera. 
Using a commercially available ELISA kit (Abcam), TTR levels (ng/mL) were measured 
in serum samples (previously analyzed for RBP4, Figure 31) from several age-matched 
groups:  healthy controls, ATTRwt (wild-type TTR-associated) amyloidosis, and 
ATTRm (mutant TTR-associated) amyloidosis featuring cardiomyopathy.  Compared to 
the control group, TTR was significantly lower in ATTRm (p = 0.04).  TTR levels in 
ATTRwt were higher than ATTRm and lower than control, but not significantly different 
from either group.  Sera were measured in triplicate and triplicate values were averaged; 
n represents the number of sera tested in each group. 
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Figure 33.  Transthyretin ELISA standard curve. 
Standard curves were produced using commercially available TTR (Sigma) purified from 
pooled sera.  Serial dilutions (dilution steps of 3x) of a stock solution (1 mg/mL) of TTR 
protein were made and run in triplicate.  Absorbances were measured at 465 and 570 nm 
(background) and change in optical density (Delta OD) was calculated by subtracting 
background values.  Representative of multiple standard curves that were generated, 
these data show low background and a sigmoidal distribution of values with linearity in 
the concentration range between 10 and 100 ng/mL.  Standard protein was diluted in 
0.1% casein buffer supplemented with Tween-20.  
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5.11 Summary and conclusions  
Doycycline 
The presence of doxycycline nearly abolished internalization of TTR-L55P TTR 
oligomers.  We concluded that this was due to significant inhibition of TTR-L55P 
aggregation and oligomer formation by the presence of 50x molar excess drug.  
Doxycycline appeared not to interact with the native wt or L55P tetrameric TTR, since 
our electrophoretic studies demonstrated that presence of doxycycline did not inhibit 
denaturation of the native protein (tetramer dissociation).  The drug did appear to halt 
monomeric aggregation and resultant progression into HMW formation.  Our conclusion 
that doxycycline did not act on the tetramer was further strengthened by circular 
dichroism studies demonstrating doxycycline did not interact with native wt or L55P 
TTR tetramers. 
Kiacta® and diflunisal 
In our cell viability studies, we did not observe any significant effect of Kiacta® 
when present in the TTR samples placed on the cells.  However, in this set of 
experiments, we did not observe the toxic effects previously noted with TTR-L55P 
oligomers.  The discrepancy between experiments may lie in variable cell characteristics 
arising from increased passage number.  Cells used in Kiacta® testing had been passaged 
20 times more than those used in previous studies.  We concluded that the higher passage 
number rendered the cells less sensitive to the toxic effect of oligomeric TTR.  
Interestingly, SDS-PAGE analysis provided evidence that Kiacta® did affect TTR-L55P 
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TTR oligomer formation by either preventing aggregation of the subunits and progression 
to oligomers or by degrading the oligomeric species formed.   
In our studies with diflunisal, we found that the presence of the drug in the L55P 
TTR oligomer samples lowered cellular viability slightly.  This effect most likely was the 
result of structural changes in the drug induced by heating of the samples at 80°C. 
Retinol-binding protein  
In aggregation studies, we showed that RBP slows the oligomerization of 
denatured TTR-L55P.  By immunohistochemical analysis, we demonstrated that RBP4 
protein was present and localized to specific areas in autopsied heart tissues from 
ATTRm (transplanted) and ATTRwt cases.  In both of these tissue samples, we observed 
the RBP4 staining in areas characterized by early ischemic changes such as wavy fibers 
and collagen infiltration between cardiomyocytes.  In the ATTRwt heart, RBP4 was 
observed in concentrated regions of the tissue surrounding an amyloid infiltrated blood 
vessel.  In addition, in the ATTRm transplanted heart, no amyloid was detected by light 
microscopic examination of Congo red stained sections; however, the appearance of early 
stage collagen infiltration was noted which frequently is an early sign of ischemia and 
may indicate an area that eventually will show amyloid fibril deposition.  We believe that 
the staining of RBP4 occurred in areas proximal to the blood pool (vasculature) where 
cardiac damage/remodeling could have indicated a site suitable for amyloid infiltration.  
We theorized that RBP4 presence in the periphery could point towards RBP4 transport of 
TTR to the heart and subsequent dissociation of the two proteins. 
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Our immunohistochemical findings were consistent with a recently published case 
report showing the evolution of ATTRwt disease in a 72 year old patient over a 15 year 
period[143].  Specifically, the patient was diagnosed with wild-type ATTR and received 
a ‘non-amyloid’ heart at transplant.  Within eight years, the patient showed amyloid 
deposition which gradually increased over time.  MRI also revealed intracardiac fibrotic 
remodeling in the interventricular septum and echocardiography confirmed septal wall 
thickening.  Though we did not observe any amyloid infiltration in our ‘non-amyloid’ 
transplant heart sample, the observation of slight collagen infiltration led us to believe 
that, similar to the case report, this tissue had been in the process of undergoing cardiac 
changes which may have included early ischemia and amyloid infiltration. 
By ELISA, we found that circulating RBP4 levels were significantly increased in 
ATTRwt and AL amyloidosis; lower concentrations were present in ATTRm amyloidosis 
featuring cardiomyopathy.  A truer interpretation of these data likely will be possible with 
matching TTR concentrations and evaluation of TTR:RBP4 values in the patient sera.  
We believe that lowered RBP4 levels should correlate to higher amounts of unbound 
(RBP4-free) TTR, available to become destabilized and form amyloid fibrils.  This 
hypothesis was partially supported by our immunohistochemical results demonstrating 
TTR deposits with no bound RBP4 in heart tissue from a case of ATTR-L58H (Figure 
28). 
The increased RBP4 levels in ATTRwt patient serum was a surprising 
observation.  One explanation is that wild-type TTR, unlike the mutant forms, maintains 
a normal sequence that favors interactions with RBP4, thereby preventing elimination of 
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RBP4 through renal filtration and higher circulating levels of the protein.  This might also 
partially explain why RBP4 was observed in ATTRwt, but not ATTRm (ATTR-L58H) 
heart tissue.  TTR and RBP4 could have remained in complex longer and RBP4 could 
have transported the TTR to the heart tissue where it dissociated, allowing TTR to 
deposit and showing RBP4 in the periphery of the amyloid deposit.  
TTR ELISA development  
We were unable to measure TTR in patient sera as our attempts to establish an 
ELISA method were unsuccessful.  We believe this was due, in part, to the complex 
nature of serum with TTR epitope masking from crowding effects or possibly through 
steric hindrance of bound RBP that shielded TTR protein from capture and detection with 
the ELISA antibodies.  A steric hindrance effect has been suggested by Liz et al. in a 
report of in vitro studies showing RBP4 binding to TTR blocking a proteolytic site on the 
latter protein[144].  In addition, it has been well established that RBP4-TTR binding 
results in a highly stable complex; the strength of this interaction is evident in studies of 
RBP4-TTR showing that dissociation requires alkaline (pH 10) conditions and 
additionally that the complex is readily co-immunoprecipitated with both RBP and TTR 
antibodies[145]. 
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CHAPTER 6.  DISCUSSION 
 
6.1 Transthyretin oligomers cause cellular toxicity through internalization and 
intracellular aggregation  
The major goal of this work was to study the effect of amyloidogenic TTR on 
cardiac cells with a focus on soluble, aggregated TTR forms that were early stage 
precursors of the amyloid fibrils.  The first task was to establish a method for creating 
TTR oligomers that was reproducible, time-efficient, and suitable for the planned cell-
based studies.  We sought a protocol that would induce TTR denaturation and 
aggregation under conditions that would nearly replicate the in vivo situation, i.e. 
physiologic pH, ionic strength, and TTR protein concentration.  Furthermore, it was 
important that solutions with TTR oligomers be appropriate for direct delivery to the 
cells; thus, a method with limited sample manipulation was also required.  To this end, 
we generated a rapid and effective protocol using heat treatment at 80 ºC to thermally 
denature and aggregate TTR proteins.  Our method did not require the use of acidic (pH ≤ 
4.5) buffers, a common condition used to form in vitro TTR oligomers and amyloid 
fibrils[47], [101].  Even though wild-type TTR exhibits extraordinary structural stability 
with a high melting point temperature (Tm > 98 ºC), we knew that partial perturbation of 
the quaternary structure of the protein, i.e. denaturation of the tetramer, was needed to 
promote amyloid oligomerization based on the published work of Kelly and Colon[101].  
Using circular dichroism analysis, the authors demonstrated that dissociation of the 
tetrameric TTR was key, as secondary and most of the tertiary structure of the protein 
was retained during aggregation and amyloid fibril formation.  
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For our studies, we used highly purified recombinantly-generated TTR proteins.  
Wild-type and several TTR proteins associated with cardiac amyloid disease were tested.  
The mutant forms included L55P, V30A, and V122I.  Using the thermal denaturation 
method of a 4-hour heat treatment at 80 °C, we generated oligomers for each type of 
TTR.  We confirmed the formation of TTR oligomers as high molecular weight species 
(> 250 kD) present on SDS-PAGE gels.  In addition, using Congo red shift measurements 
and Thioflavin T binding, we showed that these oligomers formed amyloid fibrils if 
heated for longer time intervals. 
In cell-based experiments, we observed a significant cytotoxic response in rat 
cardiomyoblasts that were treated with heat-denatured TTR-L55P or TTR-V30A samples 
containing high molecular weight (> 250 kD) oligomeric species.  In contrast, the wild-
type and V122I treatments appeared ineffective.  This variation in toxicity of the TTR 
proteins seemed to correlate to the inherent structural instability/stability of the variants; 
numerous biochemical and biophysical studies have demonstrated that TTR-L55P and 
TTR-V30A are destabilized more easily than the V122I or wild-type proteins[42], [49], 
[146].  Indeed, the L55P and V30A variants are associated with more aggressive and 
earlier onsets of disease, possibly due to their structural instabilities[23], [41]–[45].  
The toxic response of rat cardiomyoblasts to oligomeric TTR seemed, in part, due 
to internalization of the amyloidogenic forms; moreover, oligomers taken up by the cells 
appeared to increase in size, suggesting continued intracellular aggregation.  We 
observed this time-dependent aggregate growth process by fluorescent microscopy.  
Interestingly, the cells only responded to and internalized the L55P oligomers.  This may 
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be due to the fact that these oligomers have a structure or conformation that was 
recognized by certain receptors on the cellular membrane.  Further testing is required to 
confirm whether internalization was in fact receptor-mediated.  To our knowledge, these 
studies demonstrating cellular uptake of soluble, pre-fibrillar TTR-L55P and further 
propagation of the aggregation process within in the cell, are novel.  The cell staining 
results demonstrated a pattern indicating that internalized oligomers were localized to the 
endosomal or lysosomal compartments of the cell.  However, at this stage, we can only 
conjecture that aggregation was occurring within these organelles.  Further studies using 
fluorescent markers for endosomes and lysosomes would provide evidence in support of 
this hypothesis.  Understanding and characterizing the complete pathway of TTR 
oligomer recognition, internalization, intracellular trafficking, and retention by cardiac 
cells may further our understanding of ATTR pathobiology. 
Interestingly, in our human cardiac cell studies, the qPCR expression data pointed 
to a potential early stress response in the iPSC-derived cardiac embroid bodies (cEBs).  
In this series of experiments, we dosed both healthy subject-derived, as well as ATTR-
L55P patient-derived cEBs with wild-type and L55P TTR oligomers.  We measured 
several cell cycle and stress markers including matrix metallopeptidase 9 (MMP9), 
cardiac troponin (cTnT), heme oxygenase 1 (HO1), heat shock protein 27 (Hsp27), and 
p21.  Each of these markers has been implicated in cell stress and/or cardiac amyloid 
pathology.  In analyzing our results from the healthy subject-derived cEBs that were 
treated with TTR oligomers, we observed little to no change in expression levels of most 
of these markers.  Some fluctuation in MMP9 expression levels were measured in cEBs 
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treated with TTR oligomer when compared to PBS vehicle control.  Additionally, cardiac 
troponin expression appeared lowered in cells treated with native, as well as oligomers of  
TTR-L55P.  The results from our studies of the patient-derived ATTR-L55P cEBs 
demonstrated that treatment with L55P oligomers led to a striking increase in HO1, 
indicating an early stress response in these cells.  Further studies of additional cell 
markers that signal early stress response such as other heat shock proteins would be of 
interest.  Moreover, extending the exposure time of cells to TTR oligomers may induce a 
stronger and more significant stress effect clearly seen in measurements of marker 
expression. 
Our studies provide unique insight into how TTR oligomers could potentially 
exert their toxic effects on cellular viability and may provide a clue in understanding the 
mechanism of TTR-related amyloid diseases.  We have produced and studied TTR 
oligomers that were shown to be on pathway to amyloid fibril formation (Congo red shift 
and Thioflavin T assays), i.e. these soluble TTR aggregates are amyloid fibril precursors.  
While the study of TTR toxic oligomers is novel and exiting, it is important to note that 
the presence of TTR oligomers has yet to be demonstrated in vivo and may suggest that 
these are short-lived, metastable species or that an alternative pathogenetic mechanism is 
in play.  
6.2 Doxycycline interacts with destabilized transthyretin, inihibits oligomerization, 
and prevents cardic cell toxicity 
We demonstrated that cellular toxicity induced by TTR-L55P and TTR-V30A 
oligomers could be prevented when doxycycline was present in combination with TTR 
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during the thermal denaturation process.  These findings are both new and exciting for 
several reasons.  Our data not only suggest a potential role for doxycycline as a 
therapeutic in ATTR amyloidosis, but provide evidence in support of a novel mechanism 
of action.  Thus far, the antibiotic has only been reported to be a amyloid fibril 
disruptor[76], [85]–[87]; there have been no studies testing doxycycline interactions with 
soluble, pre-fibrillar forms of amyloid (Figure 34).  In addition, it has been reported that 
doxycycline reduces MMP expression in human aortic smooth muscle cells which could 
be of interest in further studies of MMP expression in TTR oligomer-treated cardiac cells. 
Unlike other small molecules that stabilize native TTR by occupying the T4-
binding pockets of the protein, doxycycline does not bind to the tetramer.  In fact, based 
on our CD and SDS-PAGE studies, it appears that the drug mechanism of action involves 
stabilizing interactions with TTR monomers that block formation of HMW species.  
Alternatively, it is possible that doxycycline binds to the HMW species of heat-denatured 
TTR and this interaction facilitates dissociation of the aggregates to dimers and 
monomers (Figure 34).  The exact form of TTR, to which doxycycline binds, remains 
undetermined.  Structural studies (CD and mass spectrometry analyses) and binding 
assays (ELISA, surface plasmon resonance) of drug with TTR monomers, tetramers, and 
HWM oligomers would aide in further understanding how doxycycline exerts this 
seemingly beneficial action. 
The striking absence of TTR-L55P oligomer internalization in the presence of 
doxycycline indicated several important and related points.  Doxycycline did indeed 
reduce the presence of TTR oligomers; thus, TTR forms present in the cell treatment 
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sample included only monomers and dimers, but no tetramers or HMW species.  As there 
was no evidence of TTR uptake by the cells and no change in cell viability in samples 
with doxycycline, we conclude that oligomers are the cytotoxic form of TTR.  Further, 
we believe that cellular toxicity is elicited in a mechanism mediated by internalization, 
and doxycycline can inhibit this process by preventing TTR aggregate formation.  To our 
knowledge, this is the first time a strategy suggesting the use of doxycycline as an agent 
for therapeutic targeting of early stage TTR amyloid formation has been proposed. 
6.3 Retinol-binding protein  
Retinol-binding protein and transthyretin  
We showed that RBP stabilizes the TTR tetramer.  In our thermal denaturation 
studies, the presence of RBP slowed the rate of TTR aggregation; this result occurred 
only when RBP was pre-incubated with vitamin A.  As other studies have described, 
vitamin A is a key element of the RBP-TTR binding complex[29], [94].  Furthermore, 
ELISA analysis of serum RBP4 levels in control and amyloid groups showed significant 
differences.  Remarkably, ATTRwt and ATTRm results showed dissimilar trends when 
compared to healthy age- and gender-matched controls.  Specifically, ATTRwt levels 
were significantly increased and ATTRm RBP4 serum concentrations were significantly 
decreased compared to controls.  While these data are intriguing, it is important to note 
that a limitation of this study was the small sample size of each group.  However, these 
trends, if upheld in a larger series, could prove useful as a diagnostic indicator. 
The analysis of serum RBP4 concentrations does not provide us with direct 
information about TTR stabilization by RBP.  However, based on previous reports[90], 
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[97] and our in vitro findings that RBP stabilizes and slows down the aggregation of 
TTR, we theorized that changes in RBP levels could lead to in vivo changes in TTR 
tetramer stability.  Assuming that TTR and RBP4 can form complexes at 1:1 or 1:2 molar 
ratios of the two proteins, it would be important to measure serum TTR concentrations in 
ATTR and calculate circulating TTR/RBP4 ratios.  We did attempt to measure serum 
TTR levels by ELISA for this purpose; unfortunately, we were unsuccessful in our 
attempts to establish a reproducible and accurate ELISA method.  Our inability to 
develop a TTR ELISA may possibly be due to the complex nature of serum, i.e. masking 
of TTR epitopes through crowding or steric hindrance of ligands or other factors.  
Without TTR values it is unclear if circulating RBP4 levels alone would be helpful in 
differentiating between ATTR disease types (ATTRwt vs. ATTRm) or for monitoring 
disease progression and outcome.  Expansion of these studies to larger group numbers 
would establish the importance of this protein as a disease biomarker. 
We propose roles for RBP4 as both a biomarker candidate and a potential 
therapeutic that can stabilize free TTR (Figure 34) and prevent dissociation of tetrameric 
TTR into monomers.  Since RBP4 is a natural binding partner of TTR with no toxic 
effects in vivo, it would be interesting to study supplementation of the protein or 
stimulating transcription of the protein as potential treatment strategies.  We also suggest 
that evaluation of RBP:TTR circulating ratios may prove to be a useful diagnostic tool 
and possibly serve to provide novel insight into disease progression and survival. 
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Retinol-binding protein and vitamin A status 
Based on our holoRBP-TTR aggregation index results, we hypothesized that 
vitamin A concentrations would show a positive correlation to TTR-RBP levels in the 
patient sera.  We sought to analyze vitamin A levels in the matched serum samples.  The 
gold standard for vitamin A measurement is quantification of total liver reserves, a 
procedure that is not an option in living patients.  Serum retinol levels are an indirect 
reflection of total vitamin A in the liver and accurate quantification of the vitamin is 
challenging as levels are homeostatically controlled (50-200 g/dL)[147].  However, 
normal homeostasis of vitamin A concentration is interrupted in several conditions where 
decreased levels (< 0.7 g/dL) have been reported[148]–[151].  Based on these reports, it 
seemed that measuring the circulating levels of vitamin A, except in cases of acute 
vitamin A deficiency, would be difficult to accurately interpret and provide limited 
insight.  An assay, recently reported to be a ‘valid’ method for indirectly assessing 
vitamin A levels, relies on data obtained from mixtures of an isotopically-labeled form of 
the vitamin (
13
C or 
2
H-labeled retinyl acetate) with the normal blood pool[149].  In 
addition to being time-consuming and costly, this dilution method requires the use of 
fresh blood samples.  Thus, vitamin A quantification in sera from our RBP studies proved 
to be beyond the scope of our resources. 
In addition, we attempted to study the effects of vitamin A, specifically all-trans-
retinol, in our TTR oligomerization and cell-based toxicity studies.  The biochemical 
nature of vitamin A presented challenges in the handling and utilization of the compound 
in our planned in vitro experiments.  An extremely hydrophobic molecule, vitamin A is 
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insoluble in water and glycerol; moreover, the compound is rapidly oxidized on exposure 
to air and rendered chemically inactive by UV light.  Therefore, we made sure to limit 
exposure to light in all our experiments and used a large excess of vitamin A in our in 
vitro studies to compensate for any loss or inactivation of the vitamin.  
Retinol-binding protein in tissue  
We were initially puzzled by the results from our immunohistochemical analyses 
of RBP4 in amyloid heart specimens.  Congo red analyses demonstrated the presence of 
amyloid deposits in the ATTRwt and ATTRm cardiac tissue sections; there was no 
evidence of amyloid in the ‘non-amyloid’ heart transplant sample.  The appearance of 
RBP4 in the ATTRwt and transplant heart tissues, but not the ATTRm sample was an 
unanticipated result.  Moreover, when present, RBP4 appeared to be localized to specific 
areas surrounding, what we believed were, ischemic areas and early stage amyloid 
infiltrated areas of the tissue.  The transplant tissue used in our study was from a patient 
with ATTR-T60A amyloidosis who had undergone concurrent liver and heart 
transplantations; the specimen examined was from the ‘new’ and ‘non-amyloid’ heart 
obtained at autopsy 8 years post-transplantation.  We posit that, had a section of this heart 
been available from a later time point, amyloid deposition would have been observed. 
Even though amyloid was not apparent in the transplant heart (by Congo red 
staining), the detection of RBP4 seems consistent with findings in a recent case 
report[143].  The case describes a male patient who had received a heart transplant to 
treat his severe, and fairly early onset (age 57), wild-type ATTR disease (diagnosed by 
Congo red histology and mass spectrometric protein sequencing).  Repeated 
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immunohistological staining of heart tissue, over a 15 year post-transplant period, 
revealed small deposits of amyloid after 8 years; the authors estimated that the deposits 
reflected a < 2% amyloid load in the tissue.  In addition, the amount of amyloid (amyloid 
load) was shown to steadily increase over the following 5 years; magnetic resonance 
imaging (MRI) revealed intra-cardiac fibrotic remodeling in the interventricular septum 
and echocardiography confirmed septal wall thickening within the transplanted heart.  
Though we did not observe any amyloid infiltration by Congo red staining, the 
observation of slight collagen infiltration led us to believe that, similar to the case report, 
the transplanted heart used in our study may have been undergoing cardiac changes 
including early ischemia and amyloid infiltration. 
It would be of great interest and value to clarify the findings from our studies and 
the previously mentioned report[143].  This could be accomplished with analyses of 
tissue samples obtained from a group of ATTRm transplanted patients at post-
transplantation follow-up over an interval, preferably > 5 years; Congo red and 
immunohisochemical staining for RBP4, as well as TTR, on these tissues would extend 
our understanding of amyloid development and progression.  Indeed, the transplant heart 
that we studied appeared to exhibit features of early ischemia, i.e. collagen infiltration, 
which we think could suggest pre-amyloid infiltrative changes.  Together, these results 
may indicate that the occurrence of RBP4 is specific to hearts with wild-type TTR 
amyloid deposits.  We believe that the presence of RBP4, in regions surrounding the 
amyloid deposits, implies a role in the transport to and localization of TTR in the amyloid 
heart deposits.  Specifically, in ATTRwt amyloidosis, we posit that TTR is carried to the 
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heart through the blood stream complexed to RBP4.  Through signaling or receptor-
mediated targeting, RBP4 becomes dissociated from the TTR-RBP complex allowing 
tetrameric TTR to become destabilized, internalized, and able to form amyloid aggregates 
within the cell. 
We did not observe RBP4 in the heart tissues containing amyloid deposits from 
cases of ATTRm and AL amyloidoses.  This may be due to weaker interactions between 
RBP4 and variant forms of TTR, or at least a decreased binding affinity between TTR-
L58H (tested case) and RBP4.  For the AL sample, the absence of detectable RBP4 was 
expected as there is no known association between immunoglobulin light chain and the 
binding partner of TTR.  Our conclusion is that the role of RBP4 in the mechanism of 
TTR amyloidogenesis is varied in ATTRwt and ATTRm amyloid diseases, and we 
hypothesize that the different pathways may be related to dissimilarities in disease onset 
and progression. 
Proposed mechanism 
We propose different mechanisms of amyloidogenesis in ATTRwt and ATTRm 
diseases, as shown in Figure 34.  We believe that wild-type TTR and RBP4 are 
complexed in circulation and that RBP4 targets circulating TTR to the heart in ATTRwt 
amyloidosis.  Once in the heart, RBP4 dissociates from the TTR-RBP4 complex allowing 
the protein to deposit in tissue, as was demonstrated in our immunohistochemistry 
studies.  The wild-type TTR protein, now lacking its binding partner, dissociates into 
monomers which enter the heart cell.  In contrast, we posit that ATTRm proteins form 
weakened interactions with RBP4 in circulation, leading to a loss of RBP4 through 
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kidney filtration.  The ATTRm protein becomes destabilized and starts to form soluble 
oligomers in circulation, which then are targeted to the heart through other signaling 
pathways, correlating with earlier age of onset.  Both the wild-type and mutant TTR 
protein species aggregate intracellularly, as we observed by fluorescent microscopy.  The 
internalized pre-fibrillar oligomers lead to cellular toxicity and increased HO1 and p21 
expression, as was shown in our qPCR studies.  The cells eventually undergo cell death 
and rupture due to the increasing intracellular stress with the amyloidogenic material 
deposited in the extracellular space, ultimately forming amyloid deposits.  Doxycycline 
(Dox) may act as a TTR monomer stabilizer preventing subunit unfolding and 
aggregation; alternatively, the drug may interact with oligomeric (HMW) forms of TTR 
and cause dissociation of the aggregates to monomeric and dimeric forms of the protein.  
Our conclusion from the experimental results reported in this dissertation is that the role 
of RBP4 in the mechanism of TTR amyloidogenesis is varied in ATTRwt and ATTRm 
amyloid diseases, and we posit that the different pathways may be related to 
dissimilarities in disease onset and progression. 
6.4 Future directions  
We hypothesize that doxycycline prevents aggregation of TTR-L55P by 
stabilizing subunit (monomers or dimers) forms of the protein or destabilizing soluble 
aggregated (HMW) species.  If the latter is the case, the dissociated forms of TTR must 
remain small enough to be effectively removed, possibly through renal filtration if in the 
bloodstream, and at the cellular level in forms that do not affect cell viability.  To further 
understand the nature of doxycycline action, a study of cells treated with TTR oligomers 
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and doxycycline could be performed to characterize the species found excreted by cells.  
If our theory holds true, we would expect higher amounts of small low molecular weight 
soluble TTR species to be present in the supernatants of cells exposed to the oligomer-
doxycycline mixture.  For the drug studies, it would also be important to expand the 
study of doxycycline to include a compliment of drug dosage experiments.  We used 10x 
and 50x molar excesses of drug, but accurately determining optimal concentrations and 
differing concentration effects are crucial in promoting this as a therapeutic agent in 
ATTR amyloidosis. 
To further explore the effect of diflunisal on the viability of cells, a modification 
of the protocol we used to generate TTR oligomers is needed.  Our heat treatment method 
using 80 °C over the course of 4 hours proved inappropriate for diflunisal; the drug seems 
chemically unstable at 80 °C at least in the buffering conditions that were used.  Thus, a 
method to denature TTR and form oligomers in the presence of diflunisal should involve 
heating at temperatures < 80 °C; however, this likely will require a longer incubation 
period, i.e. > 4 hours, and is a considerable disadvantage.  In addition, based on our 
studies, we have no reason to believe that Kiacta® would be useful in treatment of 
patients with ATTR amyloid disease. 
Future studies should also include extension and modification of the cell-based 
experiments.  The absence of effects in the ‘older’ (greater passage number) H9C2 cells 
suggests that further studies be performed on cells that have undergone consistent and 
lower (< 20) number of passages.  In addition to the rat cardiomyoblast experiments, 
further expansion of the iPSC-derived cEB experiments should include qPCR analyses of 
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a timed series of stress marker expression levels.  Increasing the number of experiments 
testing cell response to TTR oligomer treatments with and without drug (doxycycline in 
particular) would render more statistical power in calculating significant differences.  In 
addition, we propose studying doxycycline in this patient-specific cellular model. 
In moving forward with the RBP4 studies, circulating TTR values should be 
obtained to gain insight into circulating TTR-RBP4 complexes and further explore the 
potential of using these values as predictive or prospective indicators.  Moreover, it 
would be particularly interesting, as mentioned previously, to further investigate the 
presence or absence of RBP4 in heart tissue from cases of ATTRwt and ATTRm 
amyloidoses.  Finally, obtaining a measurement of vitamin A status on patients with 
ATTR might help us to uncover a role of this molecule in amyloid disease development 
and/or progression related to RBP-TTR complex formation; the correlation of vitamin A 
with RBP-TTR complex instability and ATTR disease status would likely have 
diagnostic and therapeutic implications. 
6.5. Summary statement 
Our overall goals were to:  1) create and use a cell-based model that closely 
mirrored the in vivo pathobiology of ATTR amyloidosis, 2) further define the mechanism 
of cardiac TTR-associated amyloid at the cellular level, and 3) uncover potential 
therapeutic agents that could interrupt the amyloid process.  Specifically, we designed 
studies aimed at investigating the effects of soluble amyloidogenic forms of TTR on heart 
cells and exploring the use of several agents as inhibitors of TTR-induced cytotoxicity.  
We developed a method to created soluble TTR oligomeric species, as demonstrated by 
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Congo red, Thioflavin T, and SDS-PAGE analyses.  Furthermore, we showed that TTR-
L55P oligomers are toxic to cardiomyoblasts through a pathway that includes 
internalization and progressive intracellular aggregation.  Our data showed that 
doxycycline could block the cytotoxic effect of TTR oligomers suggesting a potential 
therapeutic role for the drug in preventing in vivo deposition of amyloid.  By 
immunohistochemistry, we found that RBP4 was present in ATTRwt and ‘non-amyloid 
transplant heart tissues; the transplant heart sample was from an ATTRm case and 
obtained 8 years post-surgery.  RBP4 was localized to areas containing amyloid or in the 
case of the transplant tissue, regions that appeared to be injured, i.e. displaying ischemic 
damage, collagen infiltration, and early hypereosinophilia.  Measurements of circulating 
RBP4 concentrations demonstrated significant differences of levels in the ATTR and age-
matched, healthy controls groups, as well as in ATTRwt vs. ATTRm.  We propose a role 
for RBP4 as a potential biomarker and/or therapeutic agent based on results from our 
ELISA, immunohistochemical, and aggregation studies. 
In conclusion, the studies reported in this dissertation support the notion that 
small soluble oligomeric TTR species are a cause of toxicity and cellular damage in 
ATTR forms of systemic amyloidosis, and that TTR destabilization and localization in 
ATTRm and ATTRwt diseases are the result of two distinct and separate pathways.  
Moreover, we propose the idea that doxycycline may have utility as a possible 
therapeutic agent to target toxic amyloidogenic TTR.  Lastly, we have refueled the 
interest in the potential of RBP4 as both a biomarker and therapeutic strategy in the 
ATTR amyloid diseases.  
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Figure 34.  Schema of TTR amyloid formation pathway and interactions of retinol-
binding protein and doxycycline.  
We believe that RBP4 targets circulating TTR to the heart in ATTRwt amyloidosis; once 
in the heart, the TTR–RBP4 complex dissociates allowing tetrameric TTR to become 
destabilized.  In ATTRm, the TTR–RBP4 complex may already be dissociated in the 
circulation, and TTR is targeted to the heart through other signaling pathways.  Once 
internalized by a cardiac cell, the wild-type or mutant TTR protein species aggregate 
intracellularly and cellular stress levels rise, demonstrated by increased HO1 and p21 
expression.  Eventually the heart cell dies, secreting the amyloidogenic material into the 
extracellular space.  Doxycycline may act as a TTR monomer stabilizer preventing 
subunit unfolding and aggregation; alternatively, the drug may interact with oligomeric 
forms of TTR and cause dissociation of the aggregates.
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